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ABSTRACT
My dissertation covers a number of studies that seek to understand the genetics and
functional basis of complex traits in either human or animal models. The first project
is a genetic study of bipolar disorder using exome sequencing, primarily involving vari-
ant burden analysis and pathway analysis. The second project uses gene expression
as a functional readout of a tissue system, which allows us to identify aging signatures
in the eye. These two studies represent complementary approaches; while the first
reflects inheritance patterns of DNA variants and phenotypes, and the second is a
functional readout of an organ system. In the next two studies, I use a rat model
involving both genetics and genomic tools to perform an integrative search for genes
and functional pathways implicated in metabolic phenotypes. In this collaborative
study, I combine multiple datasets including genotype-based QTL mapping and gene
expression based functional comparison, seeking to triangulate signals that may be
noisy or subtle in one platform alone. Along the way, I had to develop methodologies
for data integration, and worked on solidifying existing resourcesin this case, the rat
reference genome. Mine is the beginning of a consolidated effort by the rat-genomics
community to arrive at a more complete and accurate reference genome, so that the
community can build on this improved resource for more accurate research in the
future. As my studies have involved both genome and exome sequencing data, one of
the challenges is to identify not only single nucleotide variants but also larger scale
DNA copy number changes. Despite the many tools for calling copy number changes,
xiii
there is still confusion about the proper investment of resources based on a principled
power analysis. In my last chapter, I develop a basic mathematical framework that
incorporates most of the important practical parameters impacting power, and create
an online calculator and examples of some usage cases. Taken together, this disserta-
tion is a reflection of how the field of genetics and genomics has moved in the last few
years, involving rapidly advancing technology, and datasets with complex structures,
requiring careful exploration and method development.
xiv
CHAPTER I
Introduction
1.1 History of Complex Trait Genetics
In the early twentieth century, researchers in the famed ‘fly room’ at Columbia
University were performing the world’s first ever gene-mapping experiments on fruit
flies. They performed crosses (‘arranged marriages’) between flies with known com-
binations of observable traits (or phenotypes); they then observed the relative fre-
quencies of these traits in their offspring, and mapped relative positions of genes on
chromosomes. They identified the first ever causal ‘genes’—fragments on chromo-
somes that they could map to a trait, finding the first mechanisms of inheritance. In
humans, the first studies on variation came in 1919, when Hirschfield and Hirschfield
[62] used variation in response to antibodies as surrogates for genetic variation. And
these were before we knew the physical or chemical basis of heredity!
Once DNA was identified as the physical unit of heredity, and Franklin, Watson,
Crick, and Wilkins elucidated its physical structure in 1953, a chain of fundamental
discoveries helped create the field of molecular biology. The field of genetics largely
merged with this field in the following decades. ‘Gene mapping’ for disease traits
became popular amongst human geneticists. The first such studies used linkage anal-
yses to narrow in on chromosomal locations for causal genes. Linkage analysis studied
the segregation of genetic markers with disease status in families. Linkage analyses
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had poor resolution because of limited number of meiosis in families, and low den-
sity of the first generation of genetic markers, and was thus followed by an approach
called positional cloning for further narrowing in on the gene. This approach was
remarkably successful in identifying causal genes for many monogenic diseases. How-
ever, most such studies applied to complex diseases were undercut by the problems
of incomplete penetrance and variable expressivity—where a mutation in a gene was
neither necessary nor sufficient to cause the disease.
The Mendelian view of genetics was prevalent for much of the 19th century and
early 20th century; most traits were expected to have a single causal gene, or in the
case of added complexity, a few causal genes (numbers that today, seem quaint, as
described by [17]. However, Mendel’s phenotypes in peas were the exceptions; most
biological traits—like height, skin color, and educational attainment—show a range
of values. In 1918, Ronald Fisher helped resolve the conflict between the particulate
nature of inheritance and the continuous distribution of most studied phenotypes. He
referred to biological traits as pointillist paintings, with many factors (multiple genes
plus the environment) coming together to contribute to the final phenotypic value
[100].
In the 1950s, Victor McCusick at Johns Hopkins University laid down four im-
portant principles about clinical genetics that formalized some important principles
of complex trait etiology (which is ironic given he is best known for his database
of Mendelian genes in man.) First, mutations in a single gene can cause different
manifestations of disease in different organs. Second, a single aspect of physiology
can be influenced by multiple genes. Third, mutations in genes can have incomplete
penetrance and variable expressivity. Fourth, mutations are just variations, and have
no inherent ‘value’ or hierarchy of goodness. The first three would be of great value
to the geneticist community in their hunt for complex trait genes, and the fourth for
geneticists in relation to society at large.
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The limitations of linkage analysis to the study of most traits eventually be-
came apparent—effect sizes of individual causal variants were too small to detect via
co-segregation within pedigrees [138]. As a solution, scientists used candidate-gene
association studies, which looked for differential frequencies of genetic variants in
genes hypothesized to be important for the studied phenotype. These studies were
almost entirely un-replicable, and threw up a deluge of results that turned out to be
false positives. In 1996, Risch and Merikangas quantitatively showed that association
studies with more genetic markers and greater sample sizes would be more powerful
than traditional family-based linkage analyses to detect common variants of small
effect [120]. This and other papers [116] lay the groundwork for a new experimen-
tal paradigm in genetics—the genome-wide association study—which would become
possible a little less than 10 years after it was originally proposed.
Genomic technology has revolutionized the study of complex traits. Different
technologies have allowed us to ask new biological questions, and use new approaches
to study existing ones—I elucidate these in section 1.2. The first genomic studies used
restriction fragment length polymorphisms (RFLP), multi-nucleotide markers that
are distantly placed signposts on the genome [16]. After the sequence of the human
genome was released, the community moved on to genotyping arrays—chips that
allow us to probe genetic variants common in the human population. Currently, the
field is making the shift towards high-throughput sequencing technologies. The field
of genetics has moved from the era of hypothesis-driven candidate gene approaches
where a single gene would be tested in families for linkage to a disease, to studies
on a genome-wide scale, looking across the genome or the exome to narrow in on
potentially causal genes for further study (‘hypothesis-generating’).
We now see large population cohorts aimed at identifying causal genetic variants
of small/large effect, family-studies aimed at identifying rare variants of larger effects.
Our view of “genes as destiny” has now been conclusively repudiated for most traits,
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and we are seeing that different affected individuals for the same trait are likely to
carry a unique portfolio of genetic risk factors, which manifest in the phenotype in
the presence of certain environmental conditions. Most of these risk factors are in the
non-coding region of the genome, which has been a stumbling block to interpretation,
and has made essential the integration of DNA sequence data with other dimensions
of biological information, such as gene expression and epigenetic information (section
1.3, 1.4). We are increasingly sequencing hundreds of thousands of people, but are
yet to solve the problem of ‘missing heritability’.
Complex trait genetics remains a field with many unsolved questions, particularly
about the genetic architecture underlying different traits. I have elucidated some of
the emerging principles in section 1.5. In this thesis, I have attempted to untangle
regions of this hairball from various angles. While I describe each of my approaches in
detail in each chapter, I briefly give an overview in the sections below. In Chapter 2,
I study families falling along the near-Mendelian spectrum of complex disease using
exome sequencing data, described in section 1.1. In Chapter 3, I study gene expression
(Section 1.2) as a biomarker of a complex trait such as aging, and in Chapter 4, I study
a rat model of aerobic capacity in the hopes of reducing some of the environmental
complexities that are brought on when studying human populations. In Chapter
5, I analyze the rat genome assembly, which is a fundamental resource upon which
any genomic analyses using a rat model depend, and discover technical flaws in the
assembly that require addressing by the rat genome community. In Chapter 6, I
build a tool to enable researchers to optimally design their experiments to have the
maximum power to detect copy-number variations from high-throughput sequencing
data from single cancer samples.
4
1.2 Genetic Data
In 2001, the human genome was sequenced. Since then, we have reference genomes
for multiple organisms; these genomic maps have become essential tools in the ge-
neticist’s toolbox. Their quality and validity is taken for granted by most biologists;
they are used as scaffolds upon which sequences from samples are aligned. I show
in Chapter V that the reference genome of the rat has previously-overlooked defects,
which need to be addressed by the community of rat-geneticists (geneticists studying
rats, not rats who happen to be geneticists).
The first generation of truly genome-wide data came with the advent of SNP (Sin-
gle Nucleotide Polymorphism) arrays. These are collections of DNA probes attached
to a solid surface. These probes typically capture 500,000 to 1 million positions in the
genome that represent “common variants”. Linkage disequilibrium between nearby
positions in the genome ensures that these common variants capture 80% of the vari-
ation in the genome. GWAS represent an implementation of the ”common disease
common variant” hypothesis, which states that common disease-causing variants will
be found. Such chips have been used to carry out genome-wide association studies
(or GWAS) in human studies, in which we look for SNPs that occur more commonly
in cases than controls. One of the first GWAS was on acute macular degeneration
(AMD) in 2005 was run on a sample of 96 cases and 50 control samples, and identi-
fied 1 locus in the Cfh gene associated with the disease [73]; a GWAS in 2016 for the
same phenotype was run on 16,144 people and revealed 52 independent loci associated
with the disease [43]. The intervening years have seen more than 3,000 GWAS on a
plethora of phenotypes.
The main picture that has emerged from GWAS is our understanding of complex
diseases was grossly oversimplified. Instead of finding loci of large effect on the phe-
notype, GWAS have revealed 100s of loci implicated in each phenotype, each of which
contribute to a minute fraction of the heritability (analog causes on the phenotype
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instead of digital). As Nisbett et al say about intelligence, the number of genes in-
volved in an outcomeis very large, and therefore the contribution of any individual
locus is just as small as the number of genes is large [105]. The initial years of GWAS
highlighted the importance of large sample sizes required to detect variants of small
effect.
GWAS is often seen as a failure of the genetics community by many corners—for
its failure to explain more of the phenotypic variance, and for being largely unable to
deliver meaningful, biologically relevant knowledge or results of utility [138]. It failed
to live up to its promise of delivering clinically actionable results, since common vari-
ants tended to increase the odds of disease by very small numbers, too small to be
clinically meaningful. However, the ways GWAS have ‘failed’ have been illuminat-
ing. GWAS results point to a highly polygenic model of disease susceptibility with
causal variants across the entire frequency of the allele frequency spectrum. They
have also made clear that pleiotropy is commonmany variants are associated with
multiple traits. Moreover, since 90% of significant GWAS loci fall in non-coding lo-
cations of the genome, it has become clear that changes in gene regulation, rather
than changes to proteins, underlie most GWAS associations. There has been a con-
certed effort by the scientific community to shine a light on non-coding regions of
the genome. Finally, SNP-based estimates of heritability show much lower values
than heritability estimates from family-based studies [40], which tell us that we may
have grossly over-estimated the genetic contribution to the variance of traits (while
under-estimating environmental contributions). It is the ‘failure’ of GWAS that has
uncovered a question that we didn’t know existed—that of the missing heritability
[122].
Although GWAS are unbiased with respect to prior biological knowledge, they are
not unbiased in terms of what is detectable (common variants) [138]. A full appreci-
ation of the genetic architecture of common disease requires an understanding of the
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role of rare variants. This has motivated a wave of rare variant association studies,
which include whole-genome sequencing as well as whole-exome sequencing [8]. Rare
variants are predicted to have larger effects than higher frequency SNPs, because we
hypothesize greater selection acting against these variants, thus accounting for their
low frequency. Despite accounting for a smaller percentage of the heritability (by
being rarer), may allow us to pinpoint causality. The study of rare variants, however,
brings with it a new set of statistical and computational challenges, since individual
variants are too rare to have the statistical power to be tested. The standard ap-
proach in such studies is to aggregate rare variants into genes or pathways, or other
biologically relevant units, and then use those as the unit of association. These stud-
ies have added to the polygenic signal from GWAS. Moreover, trio-based designs have
allowed us to find new patterns of inheritance, as in autism, where we see an increased
burden of de novo mutations in affected offspring. The number of sequenced samples
promises to explode over the next decade with samples from public BioBanks [20],
and reveal a comprehensive catalog of rare variants in the human population.
In parallel, sequencing studies have given rise to a rebirth of family-based studies,
which are a complement to population approaches. We can now study segregation of
rare variants in affected pedigrees, alleviating problems of population stratification,
and environmental and phenotypic heterogeneity that often crop up in case-control
studies. I describe our own efforts in identifying causal variations for a complex
trait—bipolar disorder—using family-based sequencing approaches in Chapter 2.
1.2.1 Experimental Design in Sequencing Studies
Sequencing cost is still a bottleneck, so researchers must often make a trade-off
between read depth, number of samples sequenced, and region of the genome to
cover. Sequencing studies have been slow to adopt power analyses to experimental
design. An analytical framework allows us to optimize experiments depending on
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the biological hypothesis we’re testing, given a fixed cost. In Chapter 6, I develop a
framework for optimizing experimental parameters to detect copy number variations
(CNVs) from sequencing data.
1.3 Gene Expression, or Transcriptomics
While genetic variation is the blueprint of biology, we ultimately want to know
how genes function in cells, and in an intact organism. Gene expression, measured
by ’counting’ some measure of the mRNA content in a cell, is a measure of gene
function that has become popular in genomics. Gene expression is known to be a
heritable phenotype from model organisms [27]. This measure then allows us to find
intermediate links between genetic variation and phenotype. It is in no way the perfect
metric of gene function (studies have shown low correlation between gene expression
and protein levels [52], and mRNA levels do not reflect variation in post-translational
modifications or protein localization), but the lack of high-throughput proteomic or
metabolic approaches has made gene expression the readout of choice.
The first genome-wide studies of gene expression used chips (microarrays) with
oligonucleotide probes specific to segments of mRNA. RNA from cells of interest
was extracted, converted to cDNA, labeled, and then washed over the chip where the
labeled cDNA molecules would bind to the probes. After unbound cDNA were washed
away, the fluorescent intensity at each probe is measured to estimate the expression
of each corresponding gene. Gene microarrays have been a useful tool in figuring out
gene expression differences that differentiate one cell type from each other. In other
words, we have found ‘tissue signatures’ of gene expression which allow us a glimpse
into their working and regulation unique to their function. In my work (described
in Chapter 3), I have used microarray data to study changes in gene expression with
age in a part of the eye called the trabecular meshwork; identifying these signatures
of aging can help us identify functions that change with age, and predispose people
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to glaucoma.
As with in genetic variation, microarrays for expression profiling have been rapidly
supplanted by RNA-sequencing, in which mRNA molecules from a cell are first bound
using polyA tags, then fragmented and sequenced. RNA-sequencing offers the ability
to detect novel isoforms, as well as allele-specific expression. We now have several
public expression datasets for a host of human tissues [88], including those that were
previously difficult to obtain.
Studying gene expression in isolation makes it difficult to ascribe causation to
a gene. For instance, up-regulation of a gene in a phenotype could either imply
that changes in expression of the gene led to the phenotype, or that changes in the
phenotype have led to modified regulation of the gene. A new paradigm is to merge
genotype data with expression information. Genetic variants (to which causality can
be attributed, since they are unaffected by environment) contributing to variation in
gene expression are christened expression quantitative trait loci, or eQTLs. Currently,
most studies are well-powered to detect cis-eQTLs of stronger effect sizes, while a
majority of trans-eQTLs remain unknown. Combining eQTL information with QTLs
can lead us to paths of causation in genetics—our ultimate goal. In Chapter 4, I
integrate genetic data with expression data from RNA-Sequencing to narrow in on
causal variants for aerobic capacity.
1.4 Epigenetic Information
In 2012, the ENCODE project released a rich resource of ‘epigenetic’ information
from diverse human tissues [36]—which means information beyond anything encoded
in the genome sequence. This includes regions of open chromatin, histone modifica-
tions, and regions of methylated DNA, all of which could be very loosely described
as ‘functional’, by virtue of having some biochemical activity. For the first time, we
could study the regulatory architecture of tissues on a genome-wide scale. Though
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the initial release was met with both fanfare and criticism [51], the ENCODE project
and similar follow-ups have been invaluable resources for the scientific community for
interpreting previous GWAS and sequencing results. GWAS hits were seen to be en-
riched in regulatory regions of the genome, and GWAS signals for certain phenotypes
were seen to be enriched in regulatory features specific to the tissue involved in that
phenotype. These datasets, along with gene expression information, have also helped
us identify the tissue of origin of many diseases in which it wasn’t clear [39].
Combining expression information with epigenomic information is heralding a new
wave of integrative analysis to understand genome function in both normal and patho-
logical samples. While the triplet code of protein-coding regions has been deciphered,
the ongoing challenge is to decipher the regulatory code underlying gene regulation.
1.5 Our current paradigms about complex traits, and how
we move forward
The availability of the complete genomes of organisms has shifted research towards
global perspectives on life processes—to study the role of all genes or all proteins at
once. The 21st century biology is likely to focus on the study of entire biological
systems, by attempting to understand how individual parts collaborate to create the
whole [79].
The deluge of trait-associated loci has shifted the focus from discovery to inter-
pretation and functional validation, in what is being dubbed the ‘post-GWAS era’
[44]. As the authors of the above paper say, “the availability of data is not synony-
mous with the presence of meaning”. The number of GWAS studies has not been
matched by a similar number of follow-up functional studies, which means that we
are often left with large lists of ’trait-associated loci’ with a limited understanding
of their biological contribution to the trait; I argue that the bottleneck has shifted
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back to the wet bench, and calls for more creative analyses to identify functional
variants. We have seen some elegant studies moving from genetic variation to gene
regulation to changes in expression into changes in function to changes in phenotype
[136, 28]. We are now able to obtain expression levels and epigenetic information
from single cells and better understand the heterogeneity within a single tissue, and
mosaicism. While long-read sequencing approaches are currently not cost-effective
for most groups, these are likely to be the approach of choice in the near future, and
will enable us to chip away further on structural variations, which have historically
been hard to study because reads from these regions have been harder to align to
their reference genomes.
Has the Human Genome Project moved us towards our goal of personalized
medicine? We now use the combined effect sizes from loci across the genome to
calculate a polygenic risk score (PRS) for each person. However, these PRSs often
increase the odds of disease by small amounts. New models to explain the small
effect sizes in GWAS suggest that causality may be distributed between a large num-
ber of genes [17]; it remains to be seen if a further increase in sample sizes in GWAS
and sequencing studies will lead to a convergence in genetic signal (indicating core
functions implicated in a disease) or a divergence (indicating widespread causality).
Furthermore, PRSs are being shown to ancestry-specific [92, 31], which would require
reference samples for matched groups before we apply them to a sample.
Population cohorts are becoming larger and deeper, and we are gaining access not
just to larger datasets, but also to deeper phenotype data. In 2017, the UK BioBank
released the genotypes and phenotypes of 488,377 individuals, with linked electronic
health record (EHR) information available for these samples [20]. Similar cohorts from
other populations are also becoming available, leading to the next wave of genome-
wide population-based analysis. EHR-linked samples may also allow us access to
longitudinal phenotype information for samples, which may help us define better
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phenotypes, instead of the single-time-point information we currently use. Another
source of such information will be wearable devices, which, when combined with
genetic data, can be a rich source of data to mine not merely for disease status, but
variations in phenotypes within the same individual.
Another much-needed (and some might say much-delayed) advance in complex
trait genetics will be the increase in diversity of genomic cohorts. We will soon
genetic data from large populations across the world [[21, 69, 54]. Not only is this
essential for personalized medicine and disease risk scores in these populations, it adds
to our understanding of how genetic background shapes the effects of risk variants.
There have been claims that the abundance of genomic data in populations will
make model organism research obsolete in the study of human complex trait genetics
[137]. However, model organisms offer us the only opportunity to study organism-
level phenotypic consequences of mutations—mutations predicted to be deleterious
in single cells are often not pathogenic in the organism (though the use of organoids
may partially solve this).
In the following chapters, I will describe the approaches I have used to identify
genomic signals. The tools I describe are likely to be a key piece in solving the puzzle
of complex traits in the 21st century.
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CHAPTER II
Exome Sequencing to Identify Rare Causal
Variants in Pedigrees with Bipolar Disorder
2.1 Background
Bipolar disorder (BPD) is a severe mood disorder characterized by alternating
episodes of mania and depression. The lifetime rate of BPD is around 1% in most
countries [142]. The etiology of BPD is largely unknown, and there is no reliable
biomarker. As a result our ability to understand and treat BPD remains at its early
stages. Family, twin, and adoption studies have shown that BPD has a strong genetic
component [95, 127]. However, candidate-gene studies have not yielded consistently
replicable findings [26, 63]. Linkage analyses have highlighted multiple genomic re-
gions, although the results vary [10, 97, 124];, and significant challenges remain before
this approach can lead to the discovery of causal genes. Meanwhile, genome-wide as-
sociation studies (GWAS) and meta-analyses have identified common variants signifi-
cantly associated with BPD, implicating approximately 10 genes [101, 41, 111]. More
recently, several groups have launched population- and family-based sequencing stud-
ies to investigate the potential involvement of rare variants in psychiatric disorders
[102, 113, 144], including BPD [5, 30, 45, 50]. Many such sequencing-based studies
are currently ongoing [129].
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Given the complex genetic and phenotypic heterogeneity of BPD, family-based ap-
proaches are particularly suited to detect rare, high-penetrance causal variants that
act in individual families [110]. In families with multiple cases across multiple gen-
erations, for instance, the contribution of environmental factors may be less complex
than in sporadic cases, and some of such families may transmit one or a few high-
impact coding variants that alter the function of a small number of pathways. To
examine this scenario requires unbiased discovery of rare variants by sequencing fam-
ily samples. In this study we analyzed 34 multiplex and multi-generational families
by exome sequencing, aiming to identify potentially high-penetrance exomic exonic
variants that increase BPD risk in each family. While the list of candidate genes may
vary across families, we sought to identify convergence in functional perturbations
across families that could shed light on shared biological mechanisms—even if the
genes involved are highly heterogeneous among families. Thus, this approach offers
a potential advantage over traditional linkage analysis, which requires accumulation
of positional signals across families and has reduced power in the presence of locus
heterogeneity. Whereas in this study, the strategy is to use rare variant data to first
identify plausible candidate genes within each family, and then accrue pathway-level
information across families.
2.2 Methods
2.2.1 Pedigrees and DNA samples
We identified 34 families for this study from the NIMH Bipolar Disorder Pedigree
Catalog maintained by the NIMH Center for Collaborative Studies on Mental Disor-
ders. The inclusion criteria were the families (1) with multiple affected individuals
in multiple generations and (2) containing at least one first cousin pair or more dis-
tantly related pairs who are both affected with Bipolar Disorder Type 1 (BP1). We
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obtained lymphoblastoid cell line-derived genomic DNA for 344 subjects representing
all members in these families for whom DNA samples were available (195 affected
with BPD or related mood disorders, and 149 unaffected). Diagnoses for all subjects
were obtained from the “Dx” field of the NIMH data file “bp ped 6 02.csv” down-
loaded on June 17, 2013 from NIMH Data Repository Bipolar Disorder Dist. 7.0. On
average there were 10 subjects from each pedigree, with a range of 3-22. The number
of subjects per family is shown in Table 2.1. These pedigrees contained both BPD
cases and those diagnosed with other psychiatric phenotypes: in total, there were
125 subjects with BP1, 18 with Bipolar Disorder Type 2 (BP2), 35 with Recurrent
Unipolar Depressive Disorder (RUDD), 11 with Schizoaffective Bipolar Disorder, and
6 subjects with unclassified mental disorders. The remaining 149 subjects were not
diagnosed with any psychiatric disorder.
2.2.2 ExomeChip genotyping
To confirm familial relatedness and sample quality we performed genotyping on
all 344 DNA samples using the Illumina HumanExome BeadChips (version 1) at the
University of Michigan Sequencing Core. Quality control of the genotype calls was
performed using PLINK version 1.07 [112]. Genotypes were obtained for 247,870
SNPs. All samples had a genotype missingness rate of <1%. Across 90 samples,
247,046 (99.7%) SNPs had per-SNP missing rate of < 5%; thus those with missing rate
>5% were removed from further analysis. Three samples in three different families
failed sex check (estimated by PLINK using heterozygosity of the X chromosome)
and were removed from further analysis, leaving a dataset of 341 samples.
2.2.3 Verifying relatedness using genotype data
We adopted two strategies to assess the level of relatedness between pairs of indi-
viduals. First, we used BEAGLE fastIBD [19] to identify genomic segments shared
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identically by descent (IBD) among the 341 samples, and used the total proportion
of the genome in IBD as a measure of relatedness. Second, we calculated the pro-
portions of the genome in IBD of 1 or 2 (i.e., Z score of 2 or 1) between each pair
with the –genome function in PLINK, using 4,860 “Grid SNPs”, incorporated in the
ExomeChip to cover the genome with regularly spaced common variants. We found
that the level of IBD as calculated in PLINK is similar to that from BEAGLE, with
a Pearson’s correlation coefficient of 0.91 over all within-family pairs (838 pairs in
34 families, counting married-in individuals). We subsequently compared the BEA-
GLE fastIBD scores with the expected relatedness based on the known pedigrees,
and found a high level of concordance 2.1 despite a moderate bias where the observed
values are often lower than the expected values. This is likely due to under-calling of
smaller IBD segments using ExomeChip data.
We identified several sample pairs with unexpectedly high levels of IBD sharing:
a sibling pair in Family 389313 had a value of 0.9; and an aunt-nephew pair in Family
15-00160 had a value of 0.9. We found that one sample in each pair was likely
mislabeled based on his/her abnormal IBD with other members of the pedigree. We
removed the two samples in question, leaving a dataset of 339. Besides these, several
first-cousin pairs in Family 38-9064 had IBD scores in the range of 0.38-0.53, much
higher than the expected Z1 + Z2 of 0.25 for first cousins. The related parents of
the cousins, who are siblings, showed the expected level of IBD for sib pairs, thus the
result could be due to cryptic relatedness of one of the married-in members. However,
this cannot be tested as the DNA is not available for the married-in members in this
family. A similar scenario of cryptic relatedness is suspected for a married-in member
in Family 10101, who had IBD of 0.11-0.39 with other members of the family. These
samples were not removed because they were not sequenced and had little impact on
the linkage analyses.
16
2.2.4 Exome sequencing and variant calling
For exome sequencing we selected 2-4 BP1 cases from each family representing at
least one pair of first cousins or more distantly related pairs, and sometimes included
an additional affected sibling. The reason to focus on cousins or more distant relatives
is that they have lower levels of allele sharing due to IBD than siblings. In all, 90
samples were sequenced. Exome capture was performed using the Roche Nimblegen
SeqCap EZ Human Exome Library v3.0, targeting a total of 64 Mb of the genome.
Paired-end, 100-base sequencing data were collected using the Illumina HiSeq2000
System. Exome capture and sequencing were performed in two batches. All 90
samples were sequenced in the first batch. Of these, 34 samples with the lowest
coverage were re-captured using the same capture kit, and sequenced in the second
batch to increase coverage. The final read depth across 90 samples ranged from 20X
to 80X, with a median of 51X. Among the called variant sites, 94% have at least 10x
median coverage across all samples.
We aligned sequence reads to the human reference genome GrCh37 using BWA
version 0.5.9 [84], removed duplicate read pairs using PICARD version 1.74 [18],
and merged reads from two batches for samples that were sequenced in both. We
performed multi-sample joint calling of variants using GATK version 3.1 [96] in a 300-
exome pool, including the 90 BPD samples and 210 other, non-psychiatric samples
undergoing exome sequencing in concurrent studies in our group. We applied the
GATK VQSR filter to remove low-quality variants, resulting in 470,021 on-target
pass-QC variants (441,278 SNPs and 28,743 indels). The transition to transversion
ratio is 2.4. For these pass-QC variant sites we defined low-quality genotypes by a
genotype quality (“GQ”) of < 10, and marked them as missing. Variant annotation
was retrieved by using ANNOVAR [140] on July 27, 2014.
As a technical validation of the single nucleotide variants (SNVs) discovered by
sequencing we compared the called genotypes in the 90 samples with those from
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the ExomeChip data, and found a high level of concordance. As shown in Table
2.2, the average concordance rate is 98.6% among the 20,484 sites both called by
sequencing and genotyped by the ExomeChip, even when the missing genotypes are
counted as discordant. Ignoring genotypes missing in either platform led to an even
higher concordance rate: 99.6%. Since the homozygous reference genotype is by far
the most abundant genotype in this panel of rare variants, we also estimated the
concordance for heterozygous or alternative homozygous genotypes called in either
platform. Among these, the concordance is 98.2% if counting missing genotypes as
errors, 99.4% when ignoring missing calls. These results show that our downstream
analysis was based on very high-quality genotype calls.
2.2.5 Variant filtering
The goal of variant filtering is to identify functionally damaging variants that are
rare in the general population and shared among BPD cases in each family. First, to
focus on rare variants we removed those with a minor allele frequency (MAF) >1%
in the European subset of the 1000 Genomes Project (514 samples) or in the Exome
Sequencing Project (4,300 individuals of European ancestry) (Nhlbi Exome Sequenc-
ing Project (Esp), 2011) . Second, we selected variants that are nonsense, residing
within 2bp of a splice junction, causing frameshift, or missense variants with predicted
damaging effect according to either SIFT [103] or PolyPhen-2 [2]. For PolyPhen-2,
only variants classified as “probably damaging” were kept. Third, since some false
positive variant calls might arise due to the specific sequencing and variant calling
processes adopted in each laboratory, we identified variants that are rare in public
databases but are common (MAF>5%) in our “local” exome database, consisting of
210 non-BPD exomes that we sequenced and analyzed in other, concurrent studies
using the same procedures. The numbers of variants (SNVs and indels) remaining at
each of the three stages described above are shown in Figure 2.1.
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Next, we proceeded to filter variants within each family by ignoring variant sites
that are monomorphic in that family (as they were identified in other families in the
joint calling). We then kept variants shared among all the sequenced cases of the
family. Note that in some families there are other BP1 cases not yet sequenced and
if they were, could further reduce the number of shared variants. Since there were
missing genotype calls due to low coverage, we allowed a variant to be considered as
shared by the sequenced cases in a given family if at least half the sequenced cases
had a called heterozygous genotype containing the rare allele, and the remaining
sequenced cases, despite having apparently “missing” genotype, met certain criteria
supporting the presence of the rare allele. The criteria are: having at least one
sequencing read supporting the alternative allele and the alternative allele frequency
being 1/6 or higher. This increased the number of shared variants by about a third.
After obtaining the list of shared variants for each family, we further narrowed
each list by segregation patterns among all the genotyped members, because exome
sequencing was done only on 90 individuals; yet all members with DNA were geno-
typed. A perfectly segregating variant would be shared among all cases but absent
in all unaffected samples. In order to allow for imperfect segregation due to re-
duced penetrance we used each family’s linkage analysis LOD scores calculated from
the genotype data (described below) as a surrogate measure of segregation patterns
along the genome. For each family, we included variants in regions that have LOD
scores greater than 0.
2.2.6 Segregation patterns by linkage analysis
The goal of linkage analysis in this step is to find genomic regions with higher,
albeit often imperfect, segregation patterns within each family, and use these regions
as a segregation filter for that family.
Phenotypic categories (“models”): To address phenotypic heterogeneity we ran
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linkage analysis separately for three diagnostic models of BPD commonly used in
linkage studies. First, the “BP1 model” considers only BP1 individuals as affected.
Second, the “BP2 model” considers either BP1 or BP2 individuals as affected. Third,
the “Bipolar Spectrum”, or “BPS model”, considers BP1, BP2, or RUDD individuals
as affected. In all three models, only individuals without any mood disorder were
classified as unaffected, and the individuals with some mood disorders but not in the
BP1, BP2, or BPS categories were classified into the “unknown” category. This way,
individuals with the Schizoaffective Bipolar Disorder and unclassified mental disor-
ders were always coded as “unknown”. Parametric linkage analysis: We performed
parametric linkage analysis using MERLIN version 1.1.2 [1], applied on the set of
4,566 autosomal “Grid SNPs” on the ExomeChip. We adopted the dominant model
by setting penetrance values of 0.0001, 0.7 and 0.7 for the three genotypes, with the
homozygous rare allele genotype and the heterozygote genotypes having penetrance
of 0.7.
2.2.7 Co-expression in specific brain regions and developmental periods
To study co-expression patterns within any gene lists we used microarray-based
gene expression data from the BrainSpan Project [98]. This project measured the hu-
man brain transcriptome at 27 stages of development, from 12 post-conception weeks
to 40 years, and for 26 regions of the brain. We downloaded the file “exon array -
matrix.csv.zip”, containing normalized data for 493 samples over 17,604 genes (Miller
et al., 2014), from BrainSpan.org on November 1, 2014. Following the procedures de-
scribed before [53] we selected 15 brain regions and divided them into four broad
anatomical categories 2.1: sub-cortical regions, sensory-motor regions, frontal cortex,
and temporal-parietal cortex. We also divided the time points into three developmen-
tal periods: fetal, childhood (from early infancy to late childhood), and adulthood
(from adolescence to late adulthood). This led to 12 experimental groups, containing
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15-62 samples each. For each of the 12 groups we calculated the Pearson correlation
coefficient (r) for all gene pairs across samples within the group. This within-group
analysis ensures that the gene co-expression networks are not unduly inflated by the
large-scale concerted changes across broad regions and distinct developmental stages.
Gene pairs with r 0.8 were considered “interacting” in the co-expression network.
To determine if the number of interacting gene pairs among the putative BPD
genes is more than other “random” gene sets, we compared the number of edges in
our gene list with the number of edges in a ’control’ set comprising genes with non-
damaging variants, but passing every other filter. Thus the control genes are those
in the same co-segregation/linkage regions but containing non-damaging variants,
chosen to contrast with the damaging variants in the same regions. We used the
non-parametric Kolmogorov-Smirnoff (KS) test to compare the two distributions.
We chose a conservative threshold of P-value<0.004, to reach overall P<0.05 after
correcting for testing 12 groups. This strategy avoided the pitfall of building a null
distribution of the number of edges by repeated sub-sampling of the control gene
sets, as these sub-samples share many of the same genes and are not independent,
leading to a null distribution with an improperly small variance and vastly inflated
significance.
2.2.8 Pathway analysis
We applied the Ingenuity Pathway Analysis (IPA, www.qiagen.com/ingenuity, QI-
AGEN, Redwood City, CA, run on June 12, 2015) and DAVID [66] to assess pathway
enrichment in the BPD genes. These tools identify biological functions or pathways
that are enriched in any user-defined gene list. In IPA we used the default settings
and tested 653 pathways defined as “canonical metabolic and signaling pathways”.
DAVID compares an input gene set with a “baseline” gene set for enrichment of func-
tions. To control for potential systematic bias introduced at various stages of variant
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filtering, we cannot designate all known genes, or a random subset, as the “baseline”.
Rather we need to match the baseline genes to the final set of BPD genes as closely as
possible. To do so, we designated the baseline genes as those represented by variants
passing all but the last filter, thus having met the same series of criteria for popu-
lation frequency, functional prediction, local exome control, and sharing among the
sequenced cases, before the final, LOD score-based segregation filter.
2.2.9 External databases and gene lists
Autism genes : We downloaded a list of 859 autism-related genes from the man-
ually curated SFARI database (2017) on March 31, 2017. This database includes
high-confidence autism genes categorized into rare, syndromic, association and func-
tional categories, based on the evidence connecting these genes to autism.
Schizophrenia genes : We obtained a list of 338 gene associated with schizophrenia
from Supplementary Table S3 of [119]. These genes were those in the vicinity of 108
SCZ-related loci (as defined by Ripke et al) obtained from the largest GWAS of SCZ,
with 36,989 cases and 113,075 controls.
Major depression-related genes : We obtained a list of 69 gene associated with
depression from Table 1 of Wray et al, 2017, who performed a meta-analysis of 130,664
cases and 330,470 controls.
BRIDGES data: The Bipolar Research in Deep Genome and Epigenome Sequenc-
ing (BRIDGES) study sequenced the genomes of unrelated individuals (1,789 cases
with BPD and 1,927 controls) of European ancestry to a mean coverage of 9.6X. We
obtained the SKAT-O burden test p-values and global ranks for 37,875 genes from
an interim freeze in February 2017.
22
2.3 Results
2.3.1 Variant filtering and discovery of potential BPD genes
We performed exome sequencing for 90 BP1 cases in 34 families, choosing in
each family at least one pair of first cousins or more distant relatives who are both
affected. After variant calling we processed the on-target bi-allelic variants by a
series of filters 2.2. By excluding common variants in the general population we
removed 3˜5% of the observed variant sites. We then kept only those likely to have
a functional impact: introducing a stop codon, creating a frameshift, residing near a
splice junction, or being missense and predicted as damaging by either of two function
annotation tools: SIFT and PolyPhen-2. This step removed 87% of variants remaining
from the previous step. Third, in order to control for laboratory-specific false positives
in the sequencing and variant calling procedures we excluded variants found in high
frequencies (MAF>5%) in 210 non-psychiatric subjects that were sequenced by the
same protocols in our laboratory and included in the joint variant calling. Next, we
analyzed each family to identify variants shared among sequenced cases in that family.
Lastly, we further selected variants in regions of increased sharing among cases, using
family-wise LOD>0 as the cutoff. The three phenotypic models (see Methods) led to
slightly different LOD>0 regions. Among the 34 families, 31 have at least one region
passing this threshold with at least one of the models.
2.3.2 Regions of increased sharing: Family-wise signals of suggestive link-
age
When linkage scores were summed across families, no region reached genome-wide
significance (LOD = 3), reflecting potential locus heterogeneity across families and
the limited power to overcome such heterogeneity given our sample size. Per-family
linkage analysis did not reveal regions reaching LOD = 3 in any family. However, some
23
families showed regions of suggestive linkage (LOD score >= 2.2) on chromosomes 4,
12, and 13. Specifically, Family 11107 had LOD = 2.63 in 12q21-23 for both the BPS
and the BP2 models, and LOD = 2.39 in 12p12.1 for the BP2 model. Family 15-00118
had LOD = 2.6 in 13q32 for the BPS model. Family 11150 had a LOD score of 2.69 in
4q35.2. These regions did not overlap with those identified in a recent linkage study
of 972 BPD pedigrees. However, some of the regions have been implicated in other
studies, as described below.
Region 13q32 was associated with BPD and schizophrenia independently in several
previous studies [33]. Interestingly, the studies implicating 13q32 used the Bipolar
Spectrum classification, consistent with this region being observed in the BPS model
in our study. The 12q23-24 region reached genome-wide significance in two previous
genome scans [38, 128] and was also implicated in a linkage analysis of unipolar
disorder [29]. Since this region is significant in our BPS model, it may underlie both
the unipolar and the bipolar disorder. The 12p12 region has shown suggestive linkage
with BPD in Ashkenazi Jewish families [9]. The region 4q35 has been previously
implicated in other linkage studies of BPD and schizoaffective disorder [? 108].
Although these were the top linkage regions, they did not contribute to the final
list of potential BPD genes in those families, because earlier filters for damaging
variants shared among the sequenced cases had left no variant in the family-wise
linkage region. It is possible that we are missing variants within these linkage regions
segregating in other affected members that havent been sequenced, or it is possible
that we missed regulatory variants that were not recovered by exome sequencing.
These filtering steps led to rare-damaging-shared variants in 310, 282 and 239
genes with the BP1, BP2 and BPS models, respectively. The three lists of genes have
significant overlap, with a union of 336 genes. The list of genes implicated in each
family is shown in Table S3. We find an average of 8-9 genes per family (range: 0-18).
If some of the pedigrees shared a genetic cause of BPD, this could be seen in a
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convergence in causal genes across families. However, most of our genes were found
in only one pedigree; only 6 genes have damaging mutations in two pedigrees in at
least one model (HLA-C, SYNJ2, GNRHR, EVPL and RFX1 in BP1 model; EVPL,
HLA-C, RFX1 and SYNJ2 in BP2; EVPL and MORN1 in the BPS model).
2.3.3 Overlap with prior genetic findings
Between the 336 genes identified in this study and the 353 schizophrenia genes
identified in a GWAS meta-analysis [119], seven genes (ACTR5, SLC32A1, ALDOA,
SMG6, TBC1D5, ATXN7 and PCDHA4) appeared in both; however this rate of
overlap is not significantly higher than expectation. No gene overlapped with the 69
genes associated with the major depressive disorder. Of the 859 autism genes from
the SFARI database , 25 appeared in our list 2.3, 2.1 fold of the expected number
of overlap (P < 0.006). This includes CREBBP, (CREB Binding Protein), which
is a circadian rhythm gene. Recently, the BRIDGES Consortium performed whole-
genome sequencing and comparisons of rare variant burden between 1,789 BP1 cases
and 1,927 controls. In unpublished SKAT-O test results, 14 of our 336 genes had P
< 0.05, which is within the expectation by chance. Rank-based analysis found no
departure from a random distribution of our 336 genes (Kolmogorov-Smirnoff test,
not significant).
2.3.4 Expression level in the brain
We obtained normalized gene expression read count data from the Genotype-
Tissue Expression Project (GTEx) to test if our list of 336 genes tended to be highly
expressed in the brain. We obtained the distribution of read counts for our gene
list in 13 regions of the brain from the GTEx portal on November 7, 2016, and
compared this distribution with that for our control gene list (1,955 genes with non-
damaging variants in our dataset) using the non-parametric Kolmogorov-Smirnoff
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test. We didn’t find any significant difference between the two distributions (results
not shown).
2.3.5 Enrichment analysis of gene networks
To assess if the BPD genes identified in this study are more likely to interact with
each other than a properly matched set of baseline genes, we analyzed (1) protein-
protein interaction data and (2) gene co-expression data.
Protein interaction network: We used the GeneMANIA database of interacting
proteins [141] to assess if there were more interacting gene pairs in our list than
expected by chance. For each disease model, we compared the number of interactions
for each gene in the list of genes in the candidate gene list with the number of
interactions in a control gene list obtained by filtering all non-damaging variants
passing all our other filters. We do not see an increased number of interacting gene
pairs in our candidate list compared to our control list of genes using the BP1 (Figure
2.4), or those from using the BP2, and BPS models (not shown).
Co-expression network: Previous studies of autism [143] have used co-expression
networks to show that genes associated with autism converge upon biological path-
ways in layer 5/6 cortical projection neurons in fetal developmental time points.
Because of the enrichment of autism-related genes in our candidates, we applied a
similar method to study if BPD-associated genes converge upon pathways in specific
regions of the brain, and at the same time points. We downloaded expression values
from the publicly available microarray data from BrainSpan (see Methods), and used
the non-parametric Kolmogorov-Smirnoff (KS) test to compare the distribution of
co-expression between our list of candidate genes and our list of control genes. Figure
2.3 shows that after correcting for multiple-testing across 12 groups, we see no signif-
icant enrichment of co-expression across all 12 groups. However, the time period of
infancy to childhood and in the sub-cortical region, shows the greatest co-expression
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of our candidate genes, which is nominally significant. The results for the BP2 and
BPS models were similar (not shown).
2.3.6 Pathway analysis
In IPA analyses, of the 653 tested pathways tested, circadian rhythm signaling was
the top pathway in all three models, though it did not cross the significant threshold
using FDR 2.3. The functional link between circadian rhythms and BPD has been
reported in many previous studies [15, 93], including our own [85]. This result is
driven by four genes, ATF4 (activating transcription factor 4), CREB3L4 (cAMP
responsive element binding protein 3-like 4), CREBBP (CREB binding protein), and
PER3 (period circadian clock 3), that are implicated in six families. DAVID did not
identify any pathway with significant enrichment among Gene Ontology, KEGG and
InterPro pathways.
2.4 Discussion
In this study, we used exome sequencing to discover coding variants and applied
multi-stage filtering to find rare damaging variants that segregate with BPD in each
of 34 multiplex families. After finding the genes carrying such potential risk variants
in individual pedigrees we sought to find convergent signals across pedigrees. This
strategy is motivated by the recognition that linkage analysis has reduced power in
cases of locus heterogeneity, due to its ineffective accrual of positional signals across
families. As an alternative, our approach tests the genetic model that there are shared
functional perturbations across families, and that such evidence can accumulate at
pathway level even if different genes are implicated in different families.
As expected, our linkage analysis did not find regions of significance across fam-
ilies, consistent with the small sample size used here and the hypothesis of locus
heterogeneity. However, some regions with suggestive linkage in individual families
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have been previously implicated in BPD. Region 13q32 was associated with BPD and
schizophrenia independently in several previous studies, including different pedigree-
based analyses [33]. Interestingly, the studies implicating 13q32 used the Bipolar
Spectrum classification, consistent with this region being observed in the BPS model
in our study. The 12q23-24 region reached genome-wide significance in two genome
scans [38, 128], and was also implicated in a linkage analysis of unipolar disorder [29].
Since this region is significant in our BPS model, it is plausible that it underlies both
unipolar and bipolar disorder.
Our variant filtering protocol led to lists of 329, 286 and 266 genes using three
nested definitions of cases. Most families had multiple genes implicated (average
7.8-9.5 genes/family across the three models). Our list of genes includes some that
recur in two of the 34 families (HLA-C and EVPL); and a subset of these has been
previously linked to BPD or SCZ in genetic studies. While these observations are
consistent with the scenario that some of the pedigrees have an oligogenic form of
inheritance, with variants in multiple genes jointly leading to the high BPD risk in
each family, our results lack the power to further prioritize the candidates.
At the pathway level, our BPD gene candidates are enriched for those involved
in circadian rhythm signaling pathway and together they affected six of the 34 pedi-
grees. Several genetic studies have revealed mutations in clock genes in BPD patients
[94, 104, 125]. Sleep disruption and circadian dysregulation are well-known comor-
bid factors of BPD. Nearly all patients with BPD have severely disrupted circadian
rhythms, which in turn influence sleep cycles [93]: a reduced need for sleep is a
common symptom of the manic episodes, while increased sleep is often seen in the
depressive episodes [59]. Moreover, regulation of sleep patterns has often brought
mood stabilizing effects in BPD patients [77].
A number of family-based sequencing studies in BPD have been published, but
with limited convergence in results [30, 45, 50, 115]. The lack of convergent signals in
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our pedigrees further highlights this pattern, suggesting that rare variants also follow
complex patterns of inheritance in BPD. An overlap with autism-related genes points
to an overlap in genetic architecture between different neurological disorders.
Our study design relied on unbiased variant discovery, rigorous filtering, and a
systematic evaluation of functional signals accumulated over the 34 families, covering
a wide range of bioinformatics data sources and carefully constructing the null dis-
tributions and control gene sets. After successfully executing this plan we uncovered
enrichment signals for circadian genes and autism genes, although the statistical effect
size were moderate, and most functional themes were not over represented. For the
narrow goal of finding pseudo-Mendelian families where very high-penetrance vari-
ants are segregating, our results were inconclusive as we lack the crucial support of
recurrence of the same genes in multiple families. Large collections of such “heavily
loaded” families will be needed to meet this goal, meanwhile it remains possible that
very few of the familial BPD cases involve the strong-acting alleles in a small num-
ber of genes. Combined analysis of both population-based and family-based data,
preferably with pedigrees embedded in population samples, has received increasing
appreciation and will likely drive the next phase of research for this severe psychiatric
disease.
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Figures
Figure 2.1:
Expected versus observed relationships Comparison of the expected
genetic relatedness based on known pedigrees and the inferred relatedness
based on sequencing data. The x and y axes show the expected and the
inferred IBD, respectively, for different degrees of relatedness. The red
dots indicated the expected value.
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Figure 2.3:
Kolmogorov-Smirnoff test for gene co-expression between our
candidate gene list and control genes Comparing the co-expression
distribution within our set of damaging genes compared to the co-
expression distribution for a control set of non-damaging genes for 4 brain
regions across 3 time points. The plot below shows the number of edges
for each gene in our candidate gene list (red) and in our control gene list
(black.) A graph shifted towards the right indicates a greater number of
pairwise interactions, as defined by a Pearson correlation coefficient of ¿
0.8.
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Figure 2.4:
Kolmogorov-Smirnoff test for protein-protein interaction be-
tween our candidate gene list and control genes This plot displays
the cdf of the number of interactions for each gene in a list of genes. The
number of interacting gene pairs (as defined by GeneMania) that were
found in our list of 310 genes (shown in red) was not significantly higher
than the number of interacting gene pairs found for each gene in our list
of control genes (A list with a significantly higher number of interactions
would be shifted to the right). A Kolmogorov-Smirnov test testing for a
greater number of interactions in our case list returned a P-value of 1.
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Tables
Family
ID
#Geno-
-typed
#Sequ-
-enced
#Cases
(BP1)
#Cases
(BP2)
#Cases
(BPS)
Comments
10101 8 2 2 3 6
10102 14 4 6 7 11
11101 12 2 2 2 5
11107 13 4 5 7 8
11108 7 2 4 5 7
11122 7 2 3 3 4
11130 7 2 3 3 5
11150 15 3 5 5 7
11153 8 3 3 3 6
11156 19 3 6 6 8
11164 7 2 3 3 4
12330 9 3 4 6 7
13101 13 2 2 2 5
13126 10 2 3 4 8
13139 7 2 4 4 5
15-00113 11 2 3 4 5
15-00118 13 3 5 6 9
15-00120 10 3 3 4 6
15-00136 10 2 2 4 5
One sample removed
(gender mismatch)
15-00160 14 4 8 8 8
Two samples removed
(gender/relatedness)
15-00164 9 3 3 3 6
15-00181 14 4 4 6 9
15-00207 10 4 4 4 4
15-00502 8 3 3 3 3
22-1003 9 2 3 3 6
22-1004 5 2 3 3 3
25-1002 5 4 5 5 5
26-1020 11 2 7 8 8
38-8031 17 3 4 4 5
38-8042 12 2 2 3 3
38-9056 5 2 3 3 4
38-9064 14 2 3 3 5
38-9313 3 2 3 3 3
One sample removed
(relatedness check)
38-9326 8 2 2 2 2
One sample removed
(gender mismatch)
Table 2.1: Number of sequenced and genotyped samples in 34 families
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Exome Chip
N 0/0 N 0/1 N 1/1 N ./. Concordance
Exome
Sequencing
N 0/0 1,438,297 2,216 1,573 3,122 0.995
N 0/1 653 244,435 525 767 0.992
N 1/1 1,276 1,758 135,839 566 0.974
N ./. 9,087 1,982 1,420 44
Concordance 0.992 0.976 0.975 0.986
Table 2.2:
Genotype concordance between ExomeChip and exome sequenc-
ing results in 90 samples.
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Number of samples for each
developmental period
Region
Code
ID Tissue Name Fetal Childhood Adulthood
SCa STR Striatum 14 5 5
MD Mediodorsal nucleus of thalamus 9 6 5
AMY Amygdaloid complex 14 7 5
HIP Hippocampus 16 7 4
FCb DFC Dorsolateral prefrontal cortex 17 7 5
MFC Anterial cingulate cortex 16 7 5
OFC Orbital frontal cortex 14 6 5
VFC Ventrolateral prefrontal cortex 15 8 5
TPc ITC Inferolateral temporal cortex 12 8 5
STC Posterior superior temporal cortex 17 8 5
IPC Posteroinferior (ventral) parietal cortex 14 8 5
SMd A1C Primary auditory cortex 14 7 5
M1C Primary motor cortex 16 7 5
S1C Primary somatosensory cortex 16 8 5
V1C Primary visual cortex 14 8 5
Table 2.3:
Number of tissue samples in gene expression data from
BrainSpan, for four aggregated brain regions and three time pe-
riods. a: Sub=cortical regions, b: Frontal Cortex, c: Temporal-parietal
cortex, d: Sensory-motor regions
Fetal period: 13-26 weeks post conception.
Infancy to childhood: 4 months-8 years.
3-40 years (There was no sample for the 8-13 year interval.)
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Gene Symbol Gene Name
ABCA7 ATP-binding cassette sub-family A member
ACHE Acetylcholinesterase
ATXN7 Ataxin 7
CACNA1H Calcium voltage-gated channel subunit alpha1 H
CAMSAP2 Calmodulin regulated spectrin-associated protein family member 2
CD44 CD44
CEP290 Centrosomal protein of 290 kDa
CLTCL1 Clathrin, heavy chain like 1
CNTN3 Contactin 3
COL28A1 Collagen, type XXVIII, alpha 1
CREBBP CREB binding protein
CUL7 Cullin 7
DCTN5 Dynactin subunit 5
DLGAP1 DLG associated protein 1
DNAH3 Dynein axonemal heavy chain 3
DOCK1 Dedicator of cytokinesis 1
GAP43 Growth associated protein 43
MYO5A Myosin VA
P2RX5 Purinergic receptor P2X 5
PCCA Propionyl-CoA carboxylase
PCDHA4 Protocadherin alpha-4
PHF3 PHD finger protein 3
PTK7 Protein tyrosine kinase 7
SBF1 SET binding factor 1
SLCO1B3 Solute carrier organic anion transporter family member 1B3
SMG6 SMG6
TECTA Tectorin alpha
TBC1D5 TBC1 domain family member 5
TTN Titin
USH2A Usherin 2A
WWOX WW domain containing oxidoreductase
Table 2.4:
Thirty one genes overlapping with the autism-associated genes
obtained from SFARI .
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Pathway N1 N2 P-value FDR
Circadian Rhythm Signaling 4 33 1.5e-03 0.49
ILK Signaling 9 196 3.4e-03 0.49
Neurotrophin/TRK Signaling 8 76 6.3e-03 0.49
Table 2.5:
Top canonical pathways in the Ingenuity Pathway Analysis for
336 genes found from the union of the three phenotype models.
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CHAPTER III
Identifying Expression Signatures of Aging in the
Trabecular Meshwork
3.1 Introduction
The trabecular meshwork (TM) is a tissue in the outer eye responsible for the
outflow of aqueous humor from the cornea [87]. The TM is a crucial determinant of
the intraocular pressure (IOP) because it lends resistance to the evacuation of aqueous
humor from the eye. With increasing age, the TM shows decreasing cellularity [4] and
increased stiffness [99], which could lead to increased resistance to aqueous humor
outflow. This increased resistance is one of the risk factors for glaucoma, an age-
related eye disease [49]. Understanding the molecular mechanisms by which this
resistance changes with age can give us clues about ways to understand age-related
changes in IOP.
There have been several studies on transcriptional changes with aging in human
tissues such as blood, brain, muscle [121, 145, 107, 149] as well on model organisms like
C. elegans [89], fruit flies [109], mice [82] and primates [42]. The only study on tran-
scriptional profiling in this tissue [23] revealed 1,387 age-associated genes. However,
because of their small sample size, they divided their samples into two groups—fetal
and old—to identify differences between them. In our study, we attempt to identify
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genes whose expressions in the TM change continuously with age, and through this,
understand potential mechanisms involved in aging of this tissue. Previous stud-
ies have shown that the aging process tends to be associated with small expression
changes in many genes, as opposed to large changes in a few genes. The number
of age-related genes that are shared across tissues remains small [48], but pathway
analyses have identified some common signatures of aging. Understanding age-related
expression changes in the TM can help understand tissue-specific signatures of aging,
as well as estimate similarity in the aging process with other tissues.
3.2 Methods
3.2.1 Sample collection
Our samples of postmortem samples were from the University of Michigan eye-
bank. For most samples, the anterior segment of the eye is removed and then stored in
optisol preservative. During a cornea transplant, the center part of the donor’s cornea
is punched out from this preserved tissue, leaving a donut of tissue that contains the
TM. We collect this remnant, and from it, we remove the TM. Occasionally the
eyebank collects a cornea and they are unable to use for transplant for some reason
(usually unrelated to the properties of the sample). In that case, they make this “full
cornea” available for research purposes. We remove the TM exactly the same way as
with the surgical remnant.
3.2.2 Transcription profiling
93 RNA samples were assayed on the Affymetrix Human Genome U219 array
using standard protocols of the University of Michigan sequencing core. Data was
normalized using RMA [70] and summarized to probesets in the Affymetrix analysis
suite, and followed by quantile normalization across the 93 samples. The array has
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49,385 probesets, 2,899 of which map to multiple genes (as defined by the U219
annotation file downloaded from the Affymetrix website on April 20, 2017). We
removed these multi-mapping probesets, using the remaining 46,486 probesets in
downstream analysis. These probesets map to 18,560 genes, with an average of 2.5
probesets mapping to one gene. We analyzed gene expression association separately
for probeset. Principal components analysis revealed no outlier samples in the top 10
principal components.
3.2.3 Regression analysis
We noticed that our oldest samples (by biological age) also had the lowest values
of RIN, and that most of the older samples were obtained from whole corneas not
used for transplantation (Figure 3.1). Thus, we used only the remaining 72 samples
from the corneoscleral button (CSB) for our regression analysis; these were samples
extracted from the remnant of the corneal tissue after it was used for a transplant. We
used the limma [131] package in R to identify genes whose expression levels changed
with age. In order to remove effects of other variables that could affect expression,
we used sex, RNA Integrity Number (RIN), race and Plate ID as covariates in the
regression.
We also ran other regression models using the top principal components as covari-
ates along with the 4 used in the model above. We saw that the regression coefficients
obtained from all models were highly correlated (Figure 3.2). We decided to use the
model with no principal components as covariates since it showed the highest number
of enriched pathways among age-associated genes (Figure 3.3).
3.2.4 Evaluating empirical significance by permutation analysis
To estimate how many of the top age-related genes could be false positives, we
permuted sample ages 100 times, and estimated the number of genes with P-value <
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0.0001 in each permutation.
3.2.5 Pathway analysis
The set of 46,397 probesets was ranked by P-value and submitted to LRpath [123]
for a directional enrichment analysis for pathways in GOCC, GOMF, GOBP and
KEGG databases. LRPath allows users to submit genes ranked by their P-value
(genes with multiple P-values are assigned the average P-value for that gene), and
allows running both unidirectional (in which the direction of change of genes is not
taken into account) and bidirectional tests (in which enrichment is tested separately
in the subsets of up-regulated and down-regulated genes). Pathways with an FDR <
0.05 were considered significant in our analyses.
3.2.6 Constructing an age predictor for TM
To test if tissue age could be predicted using gene expression as a biomarker, we
used 80-20 cross-validation. For 100 permutations, we generated a training dataset
of 73 samples, and a test set of the remaining 20 samples. Then, we used the training
set to identify genes associated with age: we identified these genes by building a
linear model regressing expression of each gene to tissue age, and selecting those
genes that showed a significant regression coefficient for age (significance was defined
using different P-value thresholds ranging from 0.05 to 0.0001). Then, we used this
list of genes to build a predictive model on the training set: predicting tissue age (the
dependent variable) using expressions of the selected genes. This model was then
used to predict tissue age on the test set.
The average predicted age for each sample across 100 permutations was taken
as the ‘predicted age’. This was then compared to the actual sample age to get an
estimate of model accuracy.
The above procedure was also used to build models to predict non-linear functions
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of age, such as age-square and log-age. We found that the linear models performed
best, and do not show the results of the other two models. We also ran the same 80-
20 cross-validation procedure on the 72 CSB samples, and found that the prediction
performance decreased to a Spearman correlation coefficient of 0.38.
3.2.7 External databases and gene lists
A list of human aging-related genes [32] was obtained from [56] downloaded on Au-
gust 30 2016. Genes which showed aging-related methylation signatures were obtained
from the additional file 3 of Horvath, 2013. We obtained aging data from expression
profiling in mouse tissues from the AGEMAP database [147]. We obtained tissue-
specific regression coefficients from [148] accessed on August 29, 2016. We obtained
pathways regulated in the mouse eye from http://cmgm.stanford.edu/ kimlab/aging -
mouse/Supplemental%20Table%204.xls. We identified human orthologs for mouse
genes using ENSEMBL Biomart [130], and then compared our gene list with the
lifted over results from AGEMAP.
3.2.8 Tissue specificity of gene expression
The Tiger Expression Database [86] (source: bioinfo.wilmer.jhu.edu/tiger/ ac-
cessed in September 2016) uses ESTs to estimate tissue-specificity of gene expression.
3.2.9 Data availability
All expression data, sample metadata, and code used in the described analysis is
available at https://github.com/shwetaramdas/aging.
3.3 Results
In this study, we collected TM tissue samples from 93 post-mortem samples with
a broad range of ages (13-88). We used microarray profiling on Affymetrix arrays to
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measure genome-wide expression levels in each of these samples. Sample metadata
are shown in Table 3.1. To identify genes whose expression levels were associated
with age, we used limma using 4 variables as covariates (variables sex, RNA Integrity
Number (RIN), ethnicity of the sample, and plate ID.) We excluded 11 samples
obtained from the cornea, since these samples had lower RINs (Figure 3.1), and could
possibly introduce a new level of confounding by virtue of having a different tissue
composition. Adding additional variables to this 5-variable model did not change the
regression coefficients for a majority of genes.
We found 2,822 probesets (corresponding to 2,324 genes) with a P-value of less
than 0.05. None of these probesets was significant at a conservative threshold of
0.05 corrected for multiple testing using the False Discovery Rate (FDR). In further
analyses, we define three levels of statistical significance; a highly stringent threshold
of FDR < 0.1 (one L1 gene), a less stringent threshold of P-value < 0.0001 (eight L2
probesets corresponding to 8 genes), and a relaxed threshold of P-value < 0.001 (83
L3 probesets corresponding to 74 genes.) Ranked P-values and regression coefficients
of all probesets are listed on the project Github page [114].
We permuted the ages of the samples 100 times, and performed a regression anal-
ysis for each permuted dataset to estimate the null distribution of regression coeffi-
cients. The qq-plot of the average ranked regression coefficients across 100 permuta-
tions versus the qq-plot of actual ranked regression coefficients shows an inflation of
high regression coefficients in our real dataset (Figure 3.4).
To visualize the expression pattern of the top age-associated genes, we generated
a heatmap of the expression data (corrected for RIN, plate ID, sex and ethnicity)
shown in Figure 3.5. We see a shift in gene expression patterns of these genes with
age (samples are displayed in increasing order of age from bottom to top). In order
to visualize the changes in gene expression of each gene, we present scatter plots of
expression residuals with age for probes from the top 8 genes (Figure 3.6).
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Previous studies on aging have shown that different tissues show different ratios
of up-regulated to down-regulated genes with age [145]. The ratio of up-regulated
to down-regulated genes in our dataset (51.7%) most closely resembles the adipose
tissue when compared to an expression study on aging in seven different human tissues
[145]. This number also supports the proportion of up-regulated genes found in the
previous study on the TM [23].
3.3.1 Genes relevant to aging of the eye
The top 8 genes from our analysis (passing the L2 threshold) include those with
functions relevant to the biological underpinnings of aging, described below. Spopl
(Speckle Type BTB/POZ Protein Like) is part of a ubiquitin-ligase. These are protein
complexes that target proteins for destruction by the proteasome. We see a decline
in expression of Spopl with age, indicating a possible increase in the accumulation
of damaged or misfolded proteins in the TM with age. The Affymetrix U219 array
has four probes aligning to this gene, all of which have a similar range of regression
coefficients, though the P-values for the other probes are lower (5.47e-0.3 to 9.19e-03).
Dnajc4 (DnaJ heat shock protein family (Hsp40) member C4) is a heat shock
protein showing increasing expression with age. Hsp40 is a molecular chaperone
whose function is to prevent proteins from misfolding. Its increased expression with
age could represent a response to oxidative stress accumulation with age [22].
The Prkcsh (protein kinase C substrate 80K-H) gene is a glycan-processing en-
zyme. Glycoproteins form a major component of the cornea and the extracellular
matrix of the TM, and previous studies have shown an increase in sulfated proteogly-
cans with age [24] leading to increased stiffness of the TM. The increased expression
of Prkcsh could lead to this phenotype.
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3.3.2 Pathway enrichment
We submitted the ranked list of genes (ranked by P-value) to LRpath to identify
pathways that were enriched in aging (pathway list with P-values is on our Github
page). Of the 520 pathways that showed enrichment, 304 were enriched among our
set of up-regulated genes. LRpath does not correct for correlation structure between
genes, which can lead to inflated test results. Thus, to get an estimate of the null
distribution of P-values, we permuted sample ages 20 times, and submitted the ranked
list of genes for each permutation to LRpath for pathway enrichment (we restricted
the number of permutations to 20, since LRpath uses a visual interface requiring
manual input of gene lists for each permutation). We found that the P-values of the
top 9 pathways were not reached in any of the 20 permutations. We also found that
for each of the top 520 pathways, the FDR was not reached for a similarly ranked
pathway in any of the 20 permutations.
We see pathways relating to intracellular function are enriched among our set of
down-regulated genes, and pathways relating to the extracellular part are enriched
among our set of up-regulated genes (Figure 3). We also see pathways such as the
electron transport chain, mitochondria, immune pathways, and the ribosome enriched
in our differentially expressed genes.
3.3.3 Prediction of age
Previous studies have attempted to use gene expression as a biomarker of tissue
age [48]. To test if gene expression in the TM could be used to predict age, we cre-
ated 100 permutations of training and test sets of 75 and 18 samples respectively, and
predicted sample ages based on the average prediction across all permutations. We
built different prediction models based on linear, logged and squared values of age,
to reflect different trajectories of expression changes with age; the linear models per-
formed best. Our predicted values had a Pearson’s correlation of 0.68 with actual ages
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(Figure 7). When restricted to the 72 corneoscleral button (CSB) samples, our pre-
dictor had a spearman correlation coefficient of 0.38. Our predictor did not perform
as well as other aging predictors built from DNA methylation profiles, but performed
comparably with other methods used on gene expression data. Our relatively small
size compared to other aging datasets could limit our predictive power.
3.4 Discussion
We find 8 genes whose expressions in the TM significantly change with age. We ob-
serve that the immune system and the extracellular matrix are most enriched among
our age-associated genes. These pathways have been previously associated with ag-
ing signatures in other tissues, and are coherent with the physiology of the TM in
particular. The TM is known to show increasing stiffness with age, and changes in
both these pathways could lead to these changes. Increased oxidative stress in the
TM has also been shown to lead to changed adhesion between cells in the TM and
the extracellular matrix.
Amongst our top pathways were pathways that have been previously shown to
be associated with aging in other tissues, such as the electron transport chain, mi-
tochondria, immune pathways, and the ribosome. This shows the commonality of
aging pathways across tissues despite there being no significant overlap between ag-
ing genes. However, while ribosomal genes show up-regulation with age in our study,
they have been consistently shown to be down-regulated with age in the muscle and in
other studies [12, 135]. We also see a host of ubiquitin-related pathways being down-
regulated with age; this is concordant with the hypothesis that aging is correlated
with an increase in misfolded proteins [13].
GenAge is a manually curated database of human aging genes, including the genes
directly related to aging in humans and the best candidate genes obtained from model
organisms [134]. One of our genes passing our L1 and L2 filters overlapped with the
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list of 305 GenAge human agerelated genes (TNFAIP8L1); an additional gene passing
our L3 filter (F8A1) overlapped with the GenAge list; this is not a significant overlap
using the hypergeometric test. Horvath [65] showed that the methylation signatures
at 353 genes could be used to predict biological age. Of our top 353 genes, 6 genes
were found in this list; this overlap is not significant. This suggests that most of
our age-related genes do not harbor age-associated CpG methylation sites, and their
association with age is regulated by mechanisms other than DNA methylation.
The AGEMAP resource [147] has a database of age-related genes and biological
pathways in mice, compiled from gene expression studies on 8,932 genes in 16 dif-
ferent mice tissues. The regression coefficients for age from our analysis showed no
correlation with the regression coefficients from expression analysis in any tissue in
mice (for this comparison, we obtained the list of regression coefficients for mice).
Previous analyses on the GTEx expression dataset across 9 human tissues have also
shown that aging processes are not highly conserved between mice and humans [145]
and the lack of correlation in our dataset supports that conclusion. However, we
found all the top pathways enriched in the eye of mice in our analysis, except for
heparin binding and lipid metabolism, suggesting a convergence in aging signatures
at the pathway level.
There have been previous studies studying transcriptional changes with aging in
other human tissues [78, 48, 149, 121]. When we compare the number of significant
age-associated genes in our study with these previous studies, we find that all other
tissues (kidney, muscle, skin, adipose and brain) except LCLs show much higher num-
bers of significant genes at the same significance threshold compared to our dataset.
Specifically, when we look at a previous study on the aging human muscle with a
sample size similar to our dataset, the range of effect sizes seen in muscle tissue is
much higher than the range seen in our dataset: our top genes have a much smaller
dependence on age in the TM compared to the muscle. Different tissues age at dif-
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ferent rates; our results, along with the noisy association of our top age-associated
genes with age, suggest that the aging signature is weak in the trabecular meshwork.
This tissue is primarily composed of extracellular proteins. It is hence possible that
age-related molecular changes are reflected more at the translational level than at the
transcriptional level.
We do notice a trend that is opposite to that seen in previous studies on aging in
other tissues. Previous studies have consistently shown a decrease in the expression
of ribosomal genes with age. However, we see a significant enrichment of ribosomal
pathways in our up-regulated genes. Some researchers have proposed an increase in
ribosomal gene expression as a compensatory mechanism for decreasing efficiency with
age [91]; this has also been seen as an increase in expression of ribosomal pathways in
the brain with age [78]. It is possible that this compensatory mechanism is a cause
for increased ribosomal expression in the TM.
The aging TM is known to have decreasing cellularity, which in turn leads to
mechanical stretching of the TM [4]. Genes related to the extracellular matrix have
been shown to be elevated in response to mechanical stretching in order to reduce
resistance to aqueous humor outflow. The age-related increase in pathways of the
extracellular space could point to this homeostatic response undertaken in response
to mechanical stretching.
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Figures
Figure 3.1:
Sample age versus RNA Integrity Number (RIN) for 93 samples
We see that the oldest samples appear to be the most degraded (low values
of RIN)
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Figure 3.2:
Comparising regression coefficients between models Shown above
are the regression coefficients from our actual model (x axis) against those
obtained from a new model incorporating an additional covariate (y axis).
We see that adding additional covariates does not change the regression
coefficients greatly.
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Figure 3.3:
Model with 0 PCs shows greatest pathway enrichment Here we
plot the FDR distribution from pathways enrichment run on the differen-
tial expression results of each model (with differing number of covariates
used for correction in each model. We see that the pink line (represent-
ing 0 PCs used for correction) shows the highest number of significant
pathways.)
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Figure 3.4:
Actual versus permuted regression coefficients Plotting the true
regression coefficents (y axis) against the mean ranked coefficients from
100 permutations.
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Figure 3.5:
Heatmap of standardized expression levels of top 8 probesets We
see that the top 8 probesets can be used to distinguish between young
and old samples (panel on right shows age)
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Figure 3.6: Expression levels of the top 8 genes against sample age
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Figure 3.7:
Building a predictor for age Our linear predictor for gene age shows a
Spearman correlation of 0.68 (using all 93 samples,) and 0.38 (using only
72 samples from the CSB)
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Tables
Quantitative Categorical
Variable Min Median Max Variable Categories
Age 13 52 88
Tissue
Type
Full cornea (21),
Remnant (72)
RIN 2.3 7 8.2 Sex Female (32), Male (61)
Hours in Optisol 6.6 97.5 223.2 Race
Caucasian (79),
African-American (12),
Asian (1), Indian (1)
x260/280 1.21 1.69 2.15 Plate
P1 (24), P2 (24), P3 (20),
P4 (7), P5 (18)
Death to Extraction
(hrs)
1.7 10.53 23.37
Death to Cooling
(hrs)
0 2.36 22.18
Death to Dissection
(hrs)
14 108 229
ng/ul 4 11.1 23.37
A260 0.099 0.277 3.868
A280 0.075 0.165 2.484
x260/280 1.21 1.69 2.15
x260.230 0.06 0.57 2.06
Table 3.1: Sample properties
57
CHAPTER IV
A Rat Model for Aerobic Capacity
4.1 Introduction
Aerobic capacity is the quintessential complex trait. Defined as the ability of
the heart and lungs to get oxygen to the muscles, it has a heritability between 39%
and 77% in humans [3], and is a phenotype with strong environmental influences.
This phenotype is an excellent predictor of disease risk in humans, and peak exercise
capacity is a better predictor of mortality than other established factors like smoking
and diabetes[83].
In human studies of aerobic capacity, it is difficult to separate out the genetic and
environmental contributions to the phenotype; i.e., separating the innate component
from the trained component. It is not possible to obtain a cohort of samples com-
pletely controlled for any possibly confounding environmental factors such as diet and
exercise. This makes genetic analysis particularly challenging because these environ-
mental factors have long-term effects on aerobic capacity.
To overcome these challenges, researchers since 1996 [74] have established a rat
model to study aerobic capacity and related traits. They started from a population
of genetically heterogeneous rats derived from outcrossing eight inbred strains [58].
Following bidirectional divergent selection for untrained exercise capacity on this pop-
ulation, two rat lines were established—the high capacity runners (HCRs) and the low
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capacity runners (LCRs). These two lines differed not only in aerobic capacity but
in a host of health-related traits, like blood pressure, body weight, oxidative stress,
lifespan [118].
Despite extensive studies, the underlying molecular basis for the enhanced health
of the HCRs and increased disease risk of LCRs eludes us. The LCRs and the HCRs
have diverged significantly due to both selection and drift, and the effects of these
two are difficult to separate out. In order to identify the true functional variants that
are the actual targets of selection, we generated an F2 intercross of 650 samples, so
that the neutral variants would no longer be associated with the selected phenotype.
4.2 Methods
4.2.1 Animals
The F2 intercross was performed in two batches. In the first batch, 4 males and 4
females were selected randomly from different families in generation 26 of each line, to
generate 79 F1 rats from 8 HCR-LCR pairs. 20 males and 20 females were randomly
picked form these F1s to form mating pairs, generating 154 F2 rats. In the second
batch, 9 males and 9 females were selected from different families in generation 28 of
each line to form 18 mating pairs, which generated 163 F1s. From these animals, 43
males and 43 females were selected and mated to yield 491 F2 rats.
4.2.2 Treadmill yest to measure AEC
Eleven week old animals were subjected to run-to-exhaustion tests without prior
training, except for brief sessions of treadmill education during the week prior to the
tests. For the run-to-exhaustion test, each trial starts at a velocity of 10miles/minute,
which increases by 1 minute/mile every 2 minutes until the rat reaches exhaustion.
Exhaustion point is defined as the third time a rat can no longer keep pace with
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the treadmill and remains on the shock grid for two seconds rather than resuming
running. The phenotype distribution for best running distance is shown in Figure
5.1.
4.2.3 Genotyping
A custom Affymetrix Axiom panel of ˜700,000 SNPs was designed to genotype our
F2 animals; SNPs in this panel were selected based on criteria previously described
in Ren et al, 2016. These SNPs were based on the rn5 version of the rat genome
assembly. After lifting over to the rn6 genome, we were left with 380,990 autosomal
SNPs (none of the SNPs mapped to chromosome X).
4.2.4 RNA-Sequencing and analysis of associated genes
We generated RNA-Seq data from the skeletal muscles of 434 F2 animals at rest.
Reads were aligned to the rn6 genome using STAR version 2.5.2a [35], and read counts
obtained using HTSeq version 0.6.1p1 [6]. We obtained read counts for 32,734 genes.
8,760 genes had read counts of 0 in all samples and were removed (23,994 genes with
counts >0 in at least 1 sample). We use log of the counts per million (CPM) (with 1
added to deal with zero counts) as the metric of gene expression. We show the first
few principal components of gene expression in figure.
Xist expression was used to confirm sample sexes for quality checking. Two ani-
mals were found to be incorrectly labeled, and were removed.
4.2.5 PEER Factors to correct expression data
Expression data can have hidden structural confounders leading to unwanted
sources of variation. One way to account for these confounders is to use principal
component analysis, and correct out the top PCs. Stegle et al [133] have proposed
a Bayesian approach to this correction using a method called PEER, which shows
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higher power than PCA-based correction. There is no standard approach to deter-
mine how many PEER factors are to be taken out. We used eight PEER factors
because this number maximized the number of cis-eQTLs on chromosome 10.
4.2.6 QTL analysis
We used EMMAX [72] to run a linear mixed model on our phenotype data cor-
rected for sex and batch. EMMAX corrects for genetic relatedness before calculating
associations between genetic variants and phenotypes which is essential in such a
structured dataset, which could otherwise show false associations due to family struc-
ture.
4.2.7 eQTL analysis
We ran eQTL analysis using Matrix-eQTL. As input to Matrix-eQTL, the phe-
notype was inverse-normalized counts per million (CPM). We regressed the inverse-
normalized CPM against the genotype, using as residuals sex, family ID, and the top
8 PEER factors. We restricted our analysis to cis-eQTLs—eQTLs within 1Mb of the
start and end co-ordinates of each gene.
4.3 Results
4.3.1 Distribution of phenotype in F2s
In Figure 4.1, we see the phenotypic distribution in different generations—F0, F1
and F2. As expected, we see a higher variance in phenotype in F2s compared to the
F1; however, the increased mean in the F2s suggests a possible dominance component
to the heritability. We also see a difference in phenotypes between the animals from
the two batches (Figure 4.2), with animals from batch 2 showing higher values of
AEC.
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4.3.2 Genetic Structure in Our Dataset
Our F2 population is highly structured, with multiple levels of structure. The two
batches are derived from two generations (26 and 28) of the HCR-LCR population,
and thus show genetic differentiationthe first few principal components show a separa-
tion between batches 4.3. Another level of structure is the relationships between F2s
due to multiple animals in the same litter. Accounting for this structure is important
in downstream analysis (for which we use Family ID as covariates, or mixed models
incorporating genetic covariance).
4.3.3 Heritability
We show the correlation between the average parental running distance and the
child’s running distance in Figure 4.4. We estimated phenotype heritability both
using SOLAR [75], and using GCTA [146] for SNP-based heritability. The SNP-based
heritability estimates are 0.54 (with SE of 0.06), and the pedigree-based estimates
of heritability are 0.60 (with SE of 0.05). However, SNP-based heritability estimates
are known to be affected by population stratification, and given the level of structure
in our dataset, it is likely that this is an over-estimate of the true heritability.
4.3.4 QTL analysis
The results from the linear mixed model show a deflated QQ-plot 4.5, showing
that we are under-powered to detect true signals. This is a negative result that
nevertheless gives us a hint of the polygenicity of this trait in this population. This
is contrary to the number of causal loci predicted by the Castle-Wright estimator
(< 15), which makes strong assumptions about independent causal loci having the
same effect sizes.
If we restricted QTL analysis to SNPs that were eQTLs (P-value < 0.001), the
deflation remained the same. Because of the deflated signal of the QTL results, we
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looked at them in the light of other results on the same samples (described later.)
4.3.5 eQTL analysis
We ran Matrix-eQTL [126] to estimate main-effect cis-eQTLs for each of 16,520
genes in our dataset. Restricting SNPs to those within 1Mb of a gene, we found
cis-eQTL-eGene pairs (defined by an FDR cutoff of 0.05). We will have to perform
further conditional analysis to detect the number of independent eQTL signals per
gene. 5,975 genes (36.2%) were eGenes (i.e., had at least one SNP that was an eQTL),
and 265,582 SNPs are eQTLs (it is likely many of these are not causal but in linkage
disequilibrium with the causal eQTL).
4.3.6 Gene expression analysis
Are there genes whose expression levels are significantly associated with AEC?
We had 409 animals from batch 2 with phenotype information and RNA-Seq data.
We used CPM (counts per million) and removed genes with non-zero counts in fewer
than 300 samples, leaving us with 16,520 genes. For each gene, we performed a
linear regression with AEC as the phenotype, using sex, family ID, two PEER factors
(described in methods) un-correlated with the phenotype, and expression principal
components not associated with the phenotype as covariates. The QQ-plot shows
considerable inflation 4.6, but 14 genes passed an FDR threshold of 0.05 (Table 4.1).
We compared our list of regression coefficients with the HCR-LCR fold changes
obtained from microarray analysis and differential expression analysis between 24
LCRs and 24 HCRs at rest (described [118]). We see a high correlation between the
regression coefficients and the fold changes 4.8. This compelled us to run a meta-
analysis between the two gene expression studies. We used a signed P-value-based
meta-analysis [37] for the meta-analysis—using P-values from edge 8 of the model
in [118], representing differential gene expression between young LCRs and HCRs at
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rest. This gave us 28 genes with an FDR < 0.01.
We performed directional pathway enrichment analysis of the differentially ex-
pressed genes using LRPath [123] by submitting a ranked list of genes, with P-values
from the meta-analysis. We found 355 significant pathways (not independent) at
an FDR threshold of 0.01. Genes related to fatty acid and lipid metabolism are
most likely to be associated with the phenotype. Other implicated pathways include
the genes in the mitochondrion, and the extracellular matrix, both of which are up-
regulated with increasing AEC. Pathways related to the ribosome tend to be enriched
in genes down-regulated with increasing AEC.
4.3.7 Integrating results
To prioritize our list of genes significantly associated with expression, we look
at our top associated genes from the meta-analysis to identify eQTLs for these. Of
the 28 significant genes (FDR <0.01), 12 have significant eQTLs, and 6 of these 12
genes have nominally significant eQTLs (P-value < 0.05). These are Raver2, Acadsb,
Vtcn1, Pcyt1a, Cox15, Rab11fip3.
From this list of six genes, we first prioritize gene Acadsb because of its role
in valine/isoleucine metabolism, which is the top pathway enriched in differential
expression. ACADSB is an enzyme that processes branched-chain amino acids in
the mitochondrion, particularly valine and isoleucine. Figure 4.9 shows the QTL and
eQTL associations for a SNP at the 5’ end of Acadsb.
We also have orthogonal evidence supporting the role of Acadsb—initial analysis
of metabolite data from SILAC assays (unpublished data) shows us that isoleucine
levels are significantly associated with best running distance in both sexes. Moreover,
we see increased allele frequency differences between the LCRs and HCRs at this gene
in generation 26 compared to generation 5 [117], indicating that this gene could be a
target for selection.
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4.4 Discussion and ongoing work
A philosophical question underlying this project is the selection itself—are we
truly capturing the traits we intend to study? The treadmill test could be capturing
phenotypes unrelated to intrinsic aerobic capacity, such as pain tolerance. Our results
(and results from similar analyses in the LCR-HCR population) are one indication of
our being on the right path, since the top pathways associated with our phenotype
are metabolic in nature, and are relevant to the physiology of the muscle.
Orthogonal studies on the LCRs and HCRs have shown that these two lines me-
tabolize fat differently—this is further borne out by our initial results in our F2
population—with fatty acid metabolic pathways and genes having the strongest sig-
nal.
This is a rich dataset, which allows us the opportunities to fine-map causal variants
using integrative approaches. We present here a first-analysis on this dataset. We have
identified potential candidate genes to test in vitro and in animal models. Ongoing
and future work will focus on incorporating and mining all possible sources of comple-
mentary information, including whole-genome sequencing data from a small subset
of HCRs and LCRs, whole genome sequencing data on the eight founder strains,
and looking more deeply into regions of the genome what show signatures of selec-
tion between the two lines. We will also look at the other gene candidates (some of
which are mitochondrial, like the Cox15 gene, and ribosomal, like the Raver2 gene),
including those obtained using other significance thresholds. We are also currently
obtaining ATAC-Seq data on a subset of these F2 animals, allowing us to dig into the
non-coding space for influences of non-coding regulation on AEC.
Besides being a useful model for fine-mapping variants for AEC, this dataset
presents many opportunities to understand the basic biology of the skeletal muscle
(this is the most highly-powered expression dataset from this tissue for rats) and
perform comparative studies of muscle metabolism. We have already seen fundamen-
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tal differences in muscle physiology between rats and humans—while the gene Myh7
can be used to differentiate males and females in humans (FUSION consortium, un-
published data), we do not see this differentiation in rats in our dataset. Mining this
dataset with related genomic, proteomic and metabolic resources will give us a deeper
understanding of aerobic capacity, and muscle physiology.
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Figures
Figure 4.1: Phenotype distribution in our F2 animals
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Figure 4.2:
Phenotype distribution for the two batches The top panel shows
phenotype distribution in batch 1, and the bottom panel shows phenotype
distribution in batch 2. We see that the distribution of running distance
in F2s from the second batch (bottom panel) has a higher median than
that in F2s from Batch 1 (top panel).68
Figure 4.3:
Pairwise Genetic Similarity in F2s. Z0 and Z1 are shown on the X
and Y axis respectively, where Z0 is the probability of IBD 0 and Z1 is
the probability of IBD 1. Siblings are colored in red, and 2-nd degree or
more distant relatives are colored in black.
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Figure 4.4:
Correlation between average parental phenotype and child’s
phenotype. Female offspring (F2) are coloured in black, and males in
blue. The average running distance of the two F1 parents is shown on the
x axis, and the child (F2) phenotype on the Y axis.
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Figure 4.5:
QQ PlotQQ Plot from a linear mixed model association analysis for AEC
shows deflation.
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Figure 4.6:
MDS plot Top 10 principal components of the genotyping data from our
615 F2 animals, colored by batch.
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Figure 4.7:
QQ Plot for genes whose expressions are associated with AEC
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Figure 4.8:
Comparing regression coefficients in F2s with HCR-LCR fold
change We see a spearman correlation of 0.43. The top genes are labeled
in the plot.
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Figure 4.9:
Gene Acadsb is associated with AEC. Panel A shows the association
of normalized Acadsb expression (corrected for sex) with AEX. Panel
B shows the QTL association for SNP AX-112691941 with AEC. Panel
C shows the association of SNP AX-112691941 with normalized Acadsb
expression.
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Tables
Gene Symbol Gene Name
Vps37b Vacuolar Protein Sorting 37 Homolog B
Hspa2 Heat Shock Protein family A (Hsp70) Member 2
C1galt1
Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine
3-Beta-Galactosyltransferase Hbp1 HMG-Box Transcription Factor 1
Naa15 N-alpha-acetyltransferase 15
Ghitm Growth hormone-transmembrane protein
Vtcn1 V-Set Domain Containing T-Cell Activation Inhibitor 1
Gab1 GRB2-associated-binding protein 1
Ypel3 Yippee-like 3
Eif5b Eukaryotic Initiation Factor 5b
Nifk Nucleolar Protein Interacting With the FHA Domain of MKI67
A930018M24Rik -
Gspt1 G1 to S phase transition 1
Dync1h1 Cytoplasmic dynein 1 heavy chain 1Imported
Table 4.1: List of genes whose expressions are associated with AEC
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CHAPTER V
Extended Regions of Suspected Mis-assembly in
the Rat Reference Genome
5.1 Background
A reference genome is the representative example of a species’ genome sequence.
Saccharomyces cerevisiae (baker’s yeast) was the first eukaryote to have its genome
sequenced. Since then, the genomic era has led to a host of genome projects to
sequence the genomes of diverse organisms, including more than 800 bacteria and
100 eukaryotes. These reference genomes allow comparative genomics approaches,
but also serve as a useful map or scaffold in assembling the genomes of individual
samples within that species.
The laboratory rat (Rattus norvegicus) is an important model organism for study-
ing the genetic and functional basis of physiological traits. Compared to the mouse,
the rat shows a greater similarity to humans [68] and has been widely used in physio-
logical, behavioral and pharmacological research. With the arrival of high-throughput
genotyping and sequencing technologies, the rat has also been used in genetic studies
to map causal loci, or identify genes that affect disease-related traits.
A fundamental resource in such genetic studies is the rat reference genome [46],
which provides the coordinate system to organize our rapidly increasing knowledge of
77
rat genes, their regulatory elements and functional profiles of diverse tissues, as well
as gene variants and dysregulation in disease models. The reference genome is also
the basic map in comparative analyses that focus on the evolutionary relationship
among rat strains or between the rat and other organisms.
Gene discovery studies can be roughly classified by the type of mapping popula-
tions adopted. Currently, popular genetic systems include naturally occurring outbred
populations, laboratory-maintained diversity outbred populations, inbred line-based
crosses (e.g., F2-crosses, or advance inbred lines), recombinant inbred lines, and many
others. Regardless of the system, a comprehensive knowledge of DNA variation in
the mapping population is essential for both the study design and biological interpre-
tation. In this study, we sought to use whole-genome sequencing (WGS) to ascertain
DNA variants in eight inbred strains: ACI, BN, BUF, F344, M520, MR, WKY and
WN, which are founders of the Heterogeneous Stock (HS) population. The HS rat
has been used for genetic studies of metabolic and behavioral traits [132]. WGS
data for these eight strains have been previously described [14, 61], using the SOLiD
technology. Here we present WGS results from the Illumina technology, containing
genotypes at more than 16.4 million single-nucleotide variant (SNV) sites. We expect
that the sequences of the eight HS founders and fully-ascertained DNA variations
can aid the imputation, haplotyping, and fine mapping efforts by the rat genomics
community.
When analyzing the SNV data we noted that, while eight founders are inbred, all
contain an unusually high amount of heterozygous nucleotide positions. Remarkably,
these sites tend to concentrate in hundreds of discrete genomic regions, which col-
lectively span 6-9% of the genome. We show that the heterozygous genotypes tend
to recur in multiple, if not all, of the eight strains, and that the suspected regions
tend to have higher-than-average read depths. We propose that these regions can
be explained by mis-assembly of the rat reference genome, where many of the highly
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repetitive segments have been erroneously “folded” in the current coordinate sys-
tem. This interpretation is not unexpected when one compares the genome assembly
statistics between mouse and rat: the latest release of the mouse reference genome
(GRCm38.p67) contains 885 contigs and a median contig length of 32.3 megabases;
whereas the rat reference genome (rn6) has 75,687 contigs and an median length of
100.5 kilobases. With this report we release mask files for the suspected regions, so
that they can be used to flag questionably results in current genomic studies until
the time when a revised, more accurate reference assembly becomes available.
5.2 Methods
5.2.1 Animals, DNA samples, whole-genome sequencing
Eight animals, one for each of the eight founders of the HS population, were used in
the study. Genomic DNA was extracted at the University of Michigan (Ann Arbor,
MI) from the liver of seven animals (ACI/N, BUF/N, F344/N, M520/N, MR/N,
WKY/N, WN/N), and from the tail of a BN/N animal. All animals were female.
The DNeasy Blood and Tissue Kit from Qiagen (Hilden, Germany) was used for DNA
extraction. Samples were further QC’s and sequenced at Novogene (Beijing, China)
following the standard Illumina protocols. Library preparation produced fragment
libraries of ¡350 bp insert length. Sequencing was done on Illumina HiSeqX-Ten to
collect 150 bp paired-end data.
In this report we abbreviate the strain names by the first two letters: AC, BN,
BU, F3, M5, MR, WK and WN.
5.2.2 Sequence alignment and variant calling
We aligned the raw sequence reads to the rat reference genome (rn6) using BWA
version 0.5.9 [84], removed duplicates using Picard v1.76 [18], and performed realign-
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ment, recalibration and joint variant calling across eight strains with the UnifiedGeno-
typer with GATK v3.4. We removed variant sites with fewer than 10 reads in eight
samples, and variant site quality score (QUAL) <= 30. We chose not to use the Hap-
lotypeCaller as we have only eight inbred lines, which are not the population-based
samples suitable for building haplotypes.
ChrX data showed the same pattern of heterozygosity as the autosomes in all
eight animals, thus confirmed that they are female. We excluded the Y chromosome
calls in downstream analysis. We did not call indels in this data release.
For comparison purposes we also ran the analysis with (1) two earlier versions of
the reference genome, rn4 and rn5; (2) two other aligners. The first is by feeding
the BWA aligned files into Stampy [90] version 1.0.32. Stampy alignment shows
higher sensitivity than BWA, especially when reads include sequence variation. (The
use of BWA-alignment as input for Stampy is to increases alignment speed without
reducing sensitivity). The second is Bowtie2 v2.1.0 [80]. All the post-alignment
processes followed the same Picard and GATK steps.
5.2.3 Comparison with the previously published variant calls using SOLiD
We compared our variant call set (for BWA alignment and rn6) with that by
Hermsen et al [61], which was based on the SOLiD sequencing data. As that call set
was aligned to rn5, we lifted over the variants to the rn6.
5.2.4 Defining regions of unusually high rates of heterozygosity
The final call set contains >16.4M SNV sites. We divided the genome into 1000-
site windows, with a median window length of 221,100 bases. For each of the eight
samples and in each window we computed the fraction of heterozygous sites in that
window (only using the number of non-missing sites in that window as the denomi-
nator). Based on the inflection point in the empirical distribution of this per-window
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heterozygosity fraction (Figure 5.1) we chose a cutoff of 25% to designate a windows
as of high-heterozygosity. We concatenated adjacent windows of high-heterozygosity
into the same segment, and in a second step, merged adjacent high-het segments
if they are separated by a single “low-heterozygosity” window, if that window had
more than 0.175 heterozygote rate. After merging, there is no evidence of very short
low-het segments separating high-het segments Figure 5.7
5.2.5 Data records Released
We share data records at different levels of processing.
1. Raw FASTQ/BAM files will be deposited in a public repository.
2. Variant calls from the UnifiedGenotyper (using BWA and rn6), as VCF files for
the eight strains.
3. Mask files on our GitHub page13, documenting the regions of high heterozygosity,
for each of the eight founder strains, as well as regions that are highly-heterozygous
in all of the eight.
5.3 Results
5.3.1 Description of variant calls
Median read depth over the genome ranges 24X - 28X across the eight samples.
Joint variant calling revealed 16,405,184 post-filter single-nucleotide variant sites on
the autosomes and chromosome X. The number of heterozygous sites per line varies
from 1,560,708 (BN) to 2,114,990 (WKY) (Table 5.1). BN represents the reference
genome, and had more Ref/Ref than Alt/Alt genotypes. In contrast, the other seven
strains had a comparable number of Ref/Ref calls as Alt/Alt calls.
We compared our genotype calls with those from Hermsen et al by calculating
between-study concordance rates at sites reported in both, and using genotypes that
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do not include the missing calls. Table 5.2 shows that each of eight lines can be
correctly matched between the two datasets, confirming the sample identity even
when the two studies were based on different animals for a given line. BN had the
highest between-study concordance: 0.95. Six other lines have concordance > 0.86.
However, MR had the lowest concordance, 0.69. To determine if an animal from
another line was mislabeled as MR, we compared our MR data with a larger panel
of 42 strains previously published and found that our MR had the highest match
with MR and WAG-Riji in that study. This suggests that the MR lines in different
laboratories may have diverged to an unusually large degree.
Variant calls from the three aligners (BWA, Bowtie2 and Stampy performed
comparably–we show genotype concordances in Table 5.3 (and concordance between
high-heterozygosity segments in 5.4)).
5.3.2 Regions of unexpected high-heterozygosity
The eight founder strains are inbred over many generations, and thus we expect
low heterozygosity in each strain across the genome [? ]. However, when we calculated
the fraction of heterozygous genotypes in consecutive 1000-SNV windows, we observed
highly varied distribution of this metric along the genome. Not only there were many
windows of high heterozygosity (>0.25), they also tended to recur in multiple lines
(Figure 5.2). Some of these windows were found in all 8 strains, including BN, the
strain of the reference genome 5.3.
We chose a cutoff value of 25% according to the distribution of per-window het-
erozygosity (Figure 5.2). After merging neighboring high-het windows if they are
separated by a single low-het window with het rate > 0.175, we obtained 304-482
contiguous high-het regions across the eight lines (median 452), covering 176.4-254.8
Mb, equivalent to 6.3%-9.2% of the genome (average 8.4%). The distribution of seg-
ment lengths is shown in 5.4. Of the heterozygous calls in each line, 28-31% fall in
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the high-het regions (mean 29%).
The high-heterozygous regions found in all eight lines contain 1,756 Ensembl genes.
These genes were enriched for G-protein coupled receptors and olfactory receptors
(fold enrichment of 3.2 and 2.0 respectively), which are known to have many par-
alogous copies in mammalian genomes [67]. There are 4,963 missense variants, 123
stop-gain variants, and 154 splice donor/acceptor variants in these regions, belonging
to 372 unique genes.
5.3.3 Heterozygous calls tend to be recurrent and show higher read depths
While Figure 5.1 shows that 1000-variant windows of high heterozygosity tend
to appear in multiple lines, we also analyzed individual heterozygous genotypes to
see how much they tend to recur in multiple lines. We divided the 16.7M variant
sites according to the number of heterozygous genotypes observed in the eight lines,
thus defining nine variant categories, from 0 to 8 heterozygotes (Figure 5.5). If the
heterozygous genotypes appear independently with a probability of p, the expected
chance of seeing a site with two heterozygotes (that is, in two of the eight lines) would
be proportional to p2, and in three lines: p3. We estimated the upper limit of p by
counting the fraction of heterogeneous genotypes over all 8 lines in all sites, knowing
that this fraction is already biased upward due to the highly recurrent heterozygous
sites. The expected probability of seeing k heterozygous sites, a(k)pk, where a(k)
is the sampling coefficient of the binomial distribution, drops much faster than the
observed k-het counts (Figure 5.5). For instance, the observed number of sites that
are heterozygous in all eight lines is more than five orders of magnitude more than
expectation.
The tendency for an individual site to appear heterozygous in multiple lines is
related to the read depth at these sites, as we see in Figure 5.6. Notably, the read
depth is higher in these regions for both homozygous and heterozygous genotypes.
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5.3.4 Concordance with previous calls
We analyzed the previously released variant calls from Hermsen et al 2015 (after
lifting over these calls to the rn6 genome from the original rn5) to see if our high-
heterozygosity segments were also found in their calls or if it could be an artifact of
our sequencing pipeline. We find similar regions showing up as heterozygous in both
calls (Figure ??), with an overlap of as much as 36% as defined by the length of the
intersect of segments called high-heterozygosity in both calls, divided by the union of
regions defined as high-heterozygosity in either call.
We have compiled a list of these low-confidence regions of the genome and provided
them as bed files on our Github page: http://github.com/shwetaramdas/rataccessibleregions/.
5.4 Discussion
We present new evidence that the existing reference genome for rats has problem-
atic regions which likely represent regions of mis-assembly. These regions make up
˜8% of the genome, and have a significantly higher read depth than other regions.
A mixed approach using BACs, PacBio long-read sequences and Illumina short-read
sequencing was used to assemble the rat reference genome. Since this was the first or-
ganism for which this approach was used, it was not entirely clear how this approach
would perform in separating regions of high sequence similarity, such as segmental
duplications.
Guryev et al1[55] in 2008 studied the rat reference genome available at the time
(rn4) and used the read-depth distribution to identify their estimates of genome mis-
assembly. These regions make up ˜1% of the genome, and only 2 of these 73 regions
lift over to the rn6 genome (both these regions are called high-heterozygous in our
data). However, they didn’t take into account heterozygosity, which may resulted
in their having under-called potentially mis-assembled regions. Another study on
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another rat inbred strain SHR/Olalpcv used short-read Illumina sequencing to obtain
the genome sequence of this strain. This group also observed higher-than-expected
levels of heterozygosity, and suggested that this could have resulted from collapsing
of reads from segmental duplication17. Because they worked on a single strain, they
could not observe the consistency of these mis-aligned regions across strains, and did
not quantify/tabulate these regions.
Previous work on the mouse genome has shown that segmental duplications were
inadvertently misassembled in a draft of the mouse genome [11]. Our estimates of
misassembled regions thus represent the most comprehensive record of sequence prob-
lems with the rat reference genome. These regions harbor more than 2,000 genes, and
studies failing to take notice of the poor quality of these regions are in danger of identi-
fying incorrect candidate genes for their studies. We propose that the rat community
mask out these regions while performing genomic analysis on rats, until a reference
genome of higher quality is made available.
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Figures
Figure 5.1:
Distribution of heterozygosity in 1000-marker windows across
the genome Distribution of the heterozygosity level in 1000-SNV win-
dows for each of the eight lines, showing that 0.25 is a reasonable cutoff
for defining high-het windows.
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Figure 5.2:
Heterozygosity in Chromosome 1 Consistent heterozygosity patterns
across the eight lines. Shown are the fraction of heterozygous genotypes
in non-overlapping 1000-SNV windows in chromosome 1, displayed for
the eight inbred lines.
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Figure 5.3:
High heterozygosity windows have more hets Windows of high
heterozygosity (bottom panel) correspond to markers with higher read
depth across Chromosome 1 for strain AC (similar results are seen for
other chromosomes and other strains)
88
Figure 5.4:
Distribution of segment lengths in eight founders Shown is the
distribution of lengths of high-heterozygosity segments in each of the eight
founder strains. We see that each of the eight strains has a similar range
of segment lengths, with a mean of ˜700Kb.
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Figure 5.5:
Heterozygosity distribution per site across 8 founders. Recur-
rence pattern of heterozygous genotypes across 8 founders. All variant
sites were categorized as having 0, 1, , or up to 8 heterozygous genotypes.
The bar graph displays the histogram of the observed sites, while the dots
show the expected number of sites if recurrence is random, estimated un-
der a simple binomial model. The expected values for 0 and 1 founders
exceed the limits of the plot.
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Figure 5.6:
Heterozygous windows show higher read depth Windows heterozy-
gous across all eight founders (right-most bar) show a significantly higher
read depth than windows heterozygous in 0-7 founders
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Figure 5.7:
Length distribution of low-heterozygosity segments After merging
segments separated by a single low-het window with heterozygosity >
0.175, we see there are not extremely short low-heterozygosity segments.
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Tables
Strain 0/0 0/1 1/1 ./.
Others
(>2 alleles)
Het
frequencies
AC 6,249,928 2,096,993 5,421,143 2,385,991 251,129 0.150
BN 12,324,354 1,560,708 803,800 1,623,744 92,578 0.106
BU 6,688,095 2,058,214 5,192,072 2,218,374 248,429 0.145
F3 6,587,382 2,101,058 5,282,082 2,181,114 253,548 0.148
M5 6,628,579 2,160,032 5,329,841 2,031,084 255,648 0.150
MR 6,736,380 2,111,216 5,243,452 2,063,655 250,481 0.147
WKY 6,599,091 1,976,801 5,130,247 2,456,145 242,900 0.142
WN 5,993,693 2,114,990 5,734,351 2,304,637 257,513 0.150
Table 5.1: Genotype frequencies in each of eight founder strains
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Hermsen 2015 calls
AC BN BU F3 M5 MR WK WN
Our variant calls
AC 0.874 0.478 0.577 0.588 0.584 0.599 0.514 0.547
BN 0.52 0.952 0.548 0.541 0.55 0.559 0.497 0.551
BU 0.586 0.511 0.871 0.628 0.631 0.609 0.52 0.599
F3 0.594 0.501 0.625 0.873 0.674 0.593 0.52 0.594
M5 0.591 0.511 0.63 0.676 0.873 0.601 0.514 0.592
MR 0.585 0.521 0.605 0.599 0.598 0.685 0.526 0.603
WK 0.518 0.453 0.516 0.518 0.51 0.536 0.859 0.508
WN 0.55 0.511 0.594 0.591 0.588 0.599 0.508 0.88
Table 5.2:
Concordance of genotypes between our variant calls and those
from Hermsen et al 2015
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BWA Bowtie Stampy
BWA 1 0.972 0.972
Bowtie 1 0.974
Stampy 1
Table 5.3: Genotype concordance between aligners
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BWA Bowtie Stampy
BWA:
Bowtie
BWA:
Stampy
Bowtie:
Stampy
AC 238,523,232 260,711,962 302,820,837 0.57 0.54 0.51
BN 171,689,865 189,496,386 213,984,578 0.61 0.6 0.58
BU 223,339,767 247,060,856 289,737,173 0.55 0.55 0.49
F3 236,379,041 252,011,886 293,848,725 0.56 0.54 0.51
M5 243,992,401 243,643,168 294,212,048 0.58 0.54 0.5
MR 225,952,435 263,629,202 276,523,184 0.55 0.55 0.5
WK 242,849,594 239,016,453 288,897,012 0.57 0.54 0.52
WN 228,435,487 249,395,735 298,824,484 0.53 0.52 0.47
Table 5.4:
The length of heterozygous segments across the genome, com-
pared across 3 aligners. Bowtie gives the least heterozygosity,
followed by BWA, and Stampy shows the worst heterozygosity
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CHAPTER VI
A Framework for Power Calculations in CNV
detection from Sequencing Data
6.1 Background
A common approach for CNA-detection relies on the telltale stepwise change of
apparent DNA ”dosage” in a genomic region [106]. For data from microarray-based
comparative genomic hybridization (arrayCGH) or single nucleotide polymorphism
(SNP) genotyping, the raw signal for DNA dosage is the total hybridization intensity
at the individual locus, which is either the arrayCGH probe location or the SNP
site. The distribution of these measured locations along the genome has been deter-
mined by how the genetic markers were selected during the design stage of each array
platform. A more recent technology is high-throughput DNA sequencing, where the
observed number of mapped reads in a given genomic interval reflects the regional
variation of DNA in the input material. In this study we mainly consider sequenc-
ing data, and do not make the distinction between germline DNA or somatic DNA,
and we will use CNA and CNV (copy number variation) interchangeably. When dis-
cussing sample purity, we refer to either the mixing of two germline DNA samples
or the coexistence of two somatic cell populations (such as cancer cell clones). We
assume that all the mapped reads are correctly mapped, thus sidestepping the situa-
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tion when segmental duplications might cause some reads to be ambiguously mapped
to multiple locations. We will not address the situation of copy-neutral structural
variation such as loss-of-heterozygosity or inversions.
For both microarray data and sequencing data, regional variation of signal in-
tensity along the genome presents a major challenge for detecting step-wise changes.
Systematic biases, such as those due to local GC-content, are technology-dependent
and can be largely corrected by appropriate normalization based on empirical bias
patterns learned from a large sample [34]. In this study we will not dwell on the issue
of bias correction, and will assume that the best procedures for correcting systematic
variation will have been applied in early stages of data preparation. Instead we will
return to the topic of signal over-dispersion, i.e., the ”noise” of read depth along the
genome beyond what is expected for random sampling from a Poisson distribution.
Read depth-based CNV detection can be formulated as a task of comparing of the
mean between two samples, as implemented in parametric tests such as the Student’s
t-test. Importantly, the unit-of-observation depends on the technology. For microar-
rays, the ”data point” is the quantitative intensity of an arrayCGH probe or the total
signal of the two alleles at a SNP site. Here the units, and their spatial distribution,
have been pre-defined by the chosen platform; and in general, the sampled locations
tend to cover the genome at variable intervals. For whole-genome sequencing (WGS)
data, the analyst can choose a window width and tally the total number of reads in
consecutive windows, where each window provides a data point. If a CNA contains
n data points, the task is to determine if the mean of such n observations is different
from the mean of a null distribution, which can be established either with adjacent
”normal” intervals or with a genome-wide baseline.
We denote the haploid sequencing read depth as D (for a dataset of 30X total
coverage, the haploid coverage is 15), the length of the CNV as L, the size of the
window into which markers/reads are binned as W, the ploidy of the CNV as N
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(normal diploid regions have N=2), read length is l, and purity of the sample as
F, defined in this study as a two-way mixing of a normal sample at (1-F) and an
aneuploidy sample at F. We do not consider three-way or more complex mixing.
If we ignore the reads falling on window boundaries, a window of length W would
contain W/l reads laid end-to-end. At a depth of D this window is expected to contain
X=2DW/l reads in a diploid region, and NDW/l reads in a region of ploidy N. When
we use the mean (Avg(X)) to estimate the expected per-window read count, X¯, a
t-like statistics can be constructed as the difference of the mean between the N-ploid
CNA and a diploid baseline, scaled by the standard error of this difference:
t =
Avg(X1)− Avg(X2)√
var(X1)/n1 + var(X2)/n2
(6.1)
where X1 and X2 are the per-window read count in the CNA and outside the
CNA, respectively. n1 and n2 are the number of independent measurements, i.e., the
number of windows, in and outside the CNA, respectively. The numerator can be
expressed as |N − 2|DW/l. A CNA of length L contains n1=L/W windows. Next,
we make the assumption that most of the genome is diploid and the baseline diploid
regions can be pooled such that n2 is much larger than n1. By omitting the (1/n2)
term the t-like score is simplified to
t =
|N − 2|DW/l
sd(X1)
.
√
L/W (6.2)
where X1 = NDW/l
where the denominator is the standard deviation of X=NDW/l in the CNA region.
The last term is
√
n1, the square root of ”sample size”, i.e., the number of windows
in the N-ploid CNA.
We would like to re-emphasize that we used D to denote haploid read depth in
order to make the expression less cluttered. For instance, in an experiment with mean
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coverage of the diploid genome of 30X, a region with a ploidy of 3 would be expected
to have a coverage of 45X (with an expected difference of 15).
The sample size n here (the number of independent events supporting the CNV)
can be written as n = (L/W), the number of bins in the CNV.
The t-like score in Eq-1 and Eq-2 represents the total signal in a power analysis,
to be partitioned into two components. t = tα + tβ where tα is the component for a
significance level of α, and tβ is the component for a power of 1-β. In essence, the
total t-like score is to be ”spent” in two ways, one for a specific Type-1 error rate,
and the rest for a specific Type-2 error rate. In the rest of the manuscript we will
derive the expressions for the total t score, whereas in depicting the power curves we
fix tα for a per-event Type-1 error of 0.05. In real situations, the experiment-wide
Type-1 error needs to be calculated with multiple testing correction according to the
number of CNAs to be detected for the entire sample.
6.2 Motivation
As outlined above, a standard power analysis involves five key components: on
one side of the expression is the total weight of evidence, split into tα+tβ, to account
for the tradeoff between the false positive and false negative rates, On the other side
of the expression is the effect size, divided by the standard deviation of this effect,
and multiplied by the square root of the sample size. In the context of coverage-based
CNA detection, the effect size is a function of four parameters: |N-2|DW/l, sample
size is L/W, proportional to L.
This study is motivated by the need to explore three factors that affect power.
First, the choice of W brings two opposing consequences: a larger W increases effect
size but reduces sample size. We will examine the net outcome of varying W. Second,
the number of reads in consecutive windows may not vary according to a simple
Poisson sampling process. Even after correcting for systematic regional biases, certain
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levels of over-dispersion may remain, leading to higher values in the denominator and
reduced power. We will introduce a variance inflation factor in the power calculator.
Three, many samples contain the mixing of two populations, and sometimes the CNA-
bearing population is very rare. Can a 10-fold reduction of ”purity” be compensated
by 10-fold deeper sequencing. We will examine questions like this, with or without
the variance inflation factor. The results below are organized into three main parts.
In #4 we examine the situation of 100% purity (F=1), with or without variance
inflation. In #5 we introduce F¡1, again with or without inflation. In #6 we explore
two use cases, one with very long CNAs (large L) but low sequencing depth (small
D); the other with high sequencing depth (large D) but low purity (small F).
6.3 100 percent tumor purity
6.3.1 Poisson
In the simplest case, read counts from sequence data can be modeled as a simple
Poisson [reference] where the mean equals the variance. The distribution of X1, the
read depth in the region of the CNV, a Poisson with mean (N)*D*(W/l). Then, the
t-statistic from Equation (1), using mean values from Equation (2) becomes
t1 =
|N − 2|√
N
DW/l√
DW/l
.
√
L/W (6.3a)
t1 =
|N − 2|√
N
√
DL
l
(6.3b)
From this equation, we see that the power of the test is directly proportional to
the read depth (D), and the length of the underlying CNV event (L), and inversely
proportional to the length of the read (l). All of these relations are consistent with
expectations, but expressed quantitatively.
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In particular, we notice that the t-statistic in this scenario is not influenced by
our choice of window size W. While a large W reduces variance, it also reduces the
effective sample size, and these two opposing effects balance out each other in the
calculation of the t-statisic. However, the power of the test is still dependent on the
window size through the number of degrees of freedom. As n > 5 , i.e. with large
CNVs, using multiple windows to tile them, this dependence of power on n disappears.
In Figure 6.1, we fix N(3), l(100), W(1000), and show power as a functions of length
of the CNV (L) and the read depth (D) under a Poisson model. We see that for a
CNV that is 10Kb long, read depth of 0.1X shows very low power while increasing
read depth to 1X increases power considerably.
6.3.2 Negative binomial
Sequencing experiments were initially expected to follow a Poisson distribution,
but studies have shown that HTS experiments show an overdispersion in variance,
which is often modeled using a negative binomial distribution (Love, 2013). Wang et
al 2008 [139] showed that the variance in their whole-genome data from a single in-
dividual was twice the read-depth. Using this estimate of dispersion, we use φ = 1/µ
as the default over-dispersion parameter.
This over-dispersion depends on the sequencing technology used due to biased ampli-
cation or sequencing of different regions of the genome. In general, exome-sequencing
has been shown to have greater variability than whole-genome approaches due to
additional bias from the targeting approaches.
We can model our X1 as a negative binomial distribution with same mean as the
Poisson but an added term to the variance.
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V ariance(∆) = µ(1 + µφ)
where µ is the mean of the Poisson (as before, µ in a region of ploidy N is
N*W*D/l), and φ is an overdispersion parameter estimated from the sequencing
data.
The t statistic from Equation (6.3b) now has an additional parameter from the
over-dispersion:
t =
|N − 2|√
N
DW/l√
DW/l
.
√
L/W.
1√
1 + µφ
As before, the N/2 term represents the fold-increase in reads at a region with
ploidy N compared to a diploid. For instance, in an experiment with median coverage
30X, a region with a ploidy of 3 would be expected to have a coverage of 45X.
The equation above simplifies to:
t =
|N − 2|√
N
√
DL
l
1√
1 + µφ
(6.4)
this equation doesn’t simplify without assumptions about the parameter φ.
The t-statistic above is the t-statistic from the Poisson model with an extra vari-
ance parameter.
Keeping constant the read length l, the window size W and the ploidy N, we
estimated the effect of the over-dispersion µφ, read depth D and CNV length L
(Figure 6.2). We find that within reasonable estimates of µφ, the variance increases
with window sizes similar to a Poisson distribution, and in cases where users expect
large CNVs, a Poisson model can be fit to the data without much loss of information.
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6.4 Taking into account tumor impurity
Tumor purity is the proportion of cancer cells in the admixture of cells in the
tumor microenvironment. This includes cancerous cells and non-cancerous cells, like
fibroblasts, epithelial cells, and immune cells [7]. In recent years, sequencing of blood
or plasma DNA (cell-free DNA or cfDNA) has been used to detect cancer-derived
mutations and CNVs. It has been demonstrated that it is feasible to detect somatic
CNVs using sparse whole-genome sequencing with 0.1X coverage [60].
When we take this tumor impurity into account, our power calculations are mod-
ified by the additional parameter F (tumor fraction).
The t statistic is:
t =
F |N − 2|DW/l√
V ar(FX1 + (1− F )X2)
.
√
L/W (6.5)
where, as before, X1 is the read depth in the region of the CNV (N*DW/l) and
X2 is the background read depth in the genome (2*DW/l).
With the assumption that F  1,
t =
F |N − 2|DW/l√
V ar(X2)
.
√
L/W (6.6)
6.4.1 Poisson
Under the assumptions of the Poisson model, without assuming low sample purity,
this becomes
t =
F |N − 2|DW/l√
V ar(FX1 + (1− F )X2)
.
√
L/W (6.7)
which doesn’t simplify.
To obtain a numerical estimate of the t-statistic from the above formula, we
simulate values for the denominator, which can be represented as a linear combination
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of Poissons:
Variance term in Denominator = V ar(FX1 + (1− F )X2)
Where X1 is the Poisson distribution in the region of the CNV, and X2 is the
Poisson distribution in the background region. We can simulate this data to obtain
a value for the variance.
Assuming low sample purity (Equation 6.6), we get:
t =
FWD
√
L/W |N − 2|/l√
WD/l
which simplifies to:
t =
F
√
LD|N − 2|√
l
We see that the t statistic is independent of the window size W, as in the case
with 100% tumor purity. We plot the dependence of power on window size and read
depth in Figure 6.3: we see for tumor fractions around 0.01, the power to detect even
long CNVs is very low.
6.4.2 Negative binomial
WD/l follows a NB with over-dispersion parameter φ
t =
F |N − 2|DW/l√
V ar(FX1 + (1− F )X2)
.
√
L/W
We use simulations from the negative binomial distribution to estimate values for the
denominator.
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Under assumptions of low sample purity, the equation (6.6) becomes:
t =
F |N − 2|(DW/l)√
(2DW/l)1 + µφ
.
√
L/W
which simplifies to
t =
F |N − 2|√DL/l√
2(1 + µφ)
(6.8)
We show, in Figure 4, power calculations for a range of read depths, keeping con-
stant the tumor fraction F. Calculations for a range of parameters can be performed
using our online calculator.
We now asked the question: how is power influenced by other experimental pa-
rameters, keeping tumor fraction constant at 0.1? From Figure 6.4, we first notice
that power increases with increasing read depth D, and tumor fractions below 0.1
yield very low power for short CNVs (L less than 100,000, even at low values of
over-dispersion).
6.5 Use Cases
We present some power calculations for some common experimental designs:
6.5.1 Shallow whole-genome sequencing to detect large CNVs in tumors
(high tumor fraction)
Previous studies have shown that it’s possible to detect large CNVs by shallow
whole-genome sequencing (0.1X) of plasma DNA. We ran a power analysis using
these parameters (N of 3, l 100, W 1000) in Figure 6.5, and show that the power to
detect CNVs smaller than 10Mb is very low with a read depth of 0.1X (and for tumor
fractions less than 0.1, we need very high read depths to reach this power).
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6.5.2 Targeted deep sequencing of previously known CNV in samples
with low tumor fraction
To check for recurrence of a tumor, patients can choose to sequence extracellular
DNA at regular intervals. We can use a power analysis to optimize frequency of
sampling, given a fixed cost. Figure 6.6 shows power calculations for this scenario,
to identify relatively short CNVs of length 10Kb (other fixed parameters include l
100, N 3 and W 1000). We see that low read depths fail to yield high power, even
at higher values of tumor fractions F. We also see in the Poisson model (data not
shown) that the increase in power from a 10-fold increase in the length of the CNV
L is equivalent to the decrease in power from a 10-fold reduction in read depth.
6.6 Caveats to this methodology
There are caveats to using this approach to power calculations. The first is that
there are alternative approaches to CNV detection that take into account split reads
[71], paired-end information [76, 47], single nucleotide polymorphisms, RNA-Seq data,
or using a combination of these metrics [64, 81, 57]. Adding information from these
data points would increase the power of CNV detection.
On the other hand, the sequencing read depth across the genome is affected by
not just copy number, but many confounding variables. One such source of bias
is the GC content of a region (which is known to have higher likelihood of being
sequenced), another is the regional variation in the fraction of short reads that can be
aligned to a given position. Whole-exome sequencing is subject to greater variation
and confounding, including from capture efficiency of probes. Corrections for these
confounders require sequencing information from multiple samples, and a failure to
do so can lead to false positive CNV calls.
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Figures
Figure 6.1:
Power analysis using a Poisson model with 100% purity We plot
the increase in power with increase in length of the underlying CNV L (x
axis) and D (different colors), keeping constant l (100bp), W (1000), and
N (3)
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Figure 6.2:
Power analysis using a Negative Binomial model with 100% pu-
rity We plot the increase in power with increase in length of the underly-
ing CNV L (x axis), over-dispersionµφ (different colors) and D (different
line types), keeping constant l (100bp), W (1000), and N (3)
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Figure 6.3:
Power analysis using a Poisson model with < 100% purity We
plot the increase in power with increase in length of the underlying CNV
L (x axis), F (different colors), D (different line types) and over-dispersion
(three panels), keeping constant l (100bp), W (1000), and N (3)
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Figure 6.4:
Power analysis using a Negative Binomial model with < 100%
purity We plot the increase in power with increase in length of the
underlying CNV L (x axis), F (different colors) and D (different line
types), keeping constant l (100bp), W (1000), and N (3)
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Figure 6.5:
Power Analysis for Use Case 1 Poisson model on the top panel,
Negative Binomial model on the bottom panel
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Figure 6.6:
Power Analysis for Use Case 2 Poisson model on the top panel,
Negative Binomial model on the bottom panel
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CHAPTER VII
Conclusions
If research in the field of complex genetics can be classified into biological discov-
ery, tool development, and map-making/resource-building, this dissertation has made
forays into each of these areas. In this dissertation, I have applied various comple-
mentary methods to understand the underlying functional basis of various traits. I
have used genetic variation (Chapters 2, 4), as well as gene expression (Chapters 3,
4) to ask these questions. In Chapter 2, I used exome sequencing data from pedigrees
with high incidences of bipolar disorder to attempt to identify causal mutations for
the disease in these pedigrees. Our results indicate that bipolar disorder is likely to
have a multi-factorial etiology even in these pedigrees with high incidence, and that
there is limited convergence in genes across pedigrees. Our results do, however, point
to a significant overlap with autism genes, and the implication of circadian genes.
Another phenotype I studied is tissue aging, where, again, we see a polygenic signal,
with many genes showing increase or decrease of expression with age.
In Chapter 3, I attempted to identify tissue signatures of aging in the trabecular
meshwork using microarray data. We identified genes whose expressions increase or
decrease with biological age, and several pathways implicated in the aging phenotype.
We also saw that gene expression in the trabecular meshwork is a poor predictor of
chronological age of the tissue (with performance failing to reach that of previous
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methylation-based predictors).
In Chapter 4, I integrated genetic data with gene expression data to map QTLs
in a rat model of aerobic capacity. Even in a model with high selection pressure,
reduced environmental variability, and a genetic background thats less diverse than
that in human populations, our results are convergent with a genetic architecture
thats polygenic. Our results highlight the role of fatty acid metabolic pathways and
mitochondrial pathways, and point us to a small number of candidate genes supported
by multiple lines of evidence for functional follow-up.
In Chapters 5 and 6, I worked on methods and resources of the complex trait
genetics field. First, I analyzed the rat reference genome and identify mis-assembled
regions in the assembly making up 8% of the genome, alerting researchers to the ne-
cessity of masking certain regions in the genome while performing genomic analyses;
this is the first step in a concerted effort by the community to create a better ref-
erence genome for this model organism. In Chapter 6, I turned my attention to the
detection of copy number variation from sequencing data—another class of variation
contributing to variation in complex traits. Despite the many tools for calling copy
number changes, there is still confusion about the proper investment of resources
based on a principled power analysis. I created a new framework for power calcu-
lations to detect copy number variations from sequencing data, taking into account
various experimental parameters affecting these. I also created an online calculator
for researchers and clinicians to estimate the power of their study/biopsy under dif-
ferent experimental settings. As the use of sequencing technologies in the realm of
clinical genetics continues to increase, an extension of this framework can maximize
the utility of genetics in such settings.
The power of discovery of a genetic study is limited either by the technology and
sample size (which determine what features we choose to shine a light on) or the
strength of the underlying biological signal itself. Genome-wide studies are often
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called ‘hypothesis-free’, but this is not strictly true—while there is no biological can-
didate (like a gene of interest), the features these studies choose to look at determine
the questions that are being asked, and set boundaries for what can be detected.
Looking at exome sequencing data alone in Chapter 2 limited our search space to
coding variants. If any of these pedigrees show regulatory defects leading to the phe-
notype, we will have missed these signals under our narrow hypothesis. The study on
the trabecular meshwork missed splicing differences with age, because of the technical
design of microarrays. Moreover, it is also possible that expression signatures in this
tissue are particularly depleted of information (as seen by the weaker signal in this
study compared to other similarly-powered studies on other tissues) because of low
cellular density (and thus, fewer ‘live’ cells being assayed)—protein expression studies
in this tissue may be a better indicator of age.
The results from my hunt for causal genetic signals for various traits (Chapters 2,3
& 4) point to a more diffuse non-Mendelian signal for the underlying trait than we had
gone in expecting a priori, demonstrated by a lack of convergence across pedigrees in
Chapter 2, and a deflated QQ-plot in Chapter 4. This has been the theme underlying
research in the human complex traits field over the last decade. As a community, we
have to respond to this new paradigm not by merely increasing sample sizes, but by
focusing on strategies that take this complexity into account. Integrating information
from regulatory data (reducing the number of tested interactions) is one way to better
study these.
The contribution of the genetic background to complexity in mechanisms means
that we need to think about the implications of results from model organisms in hu-
man complex trait genetics. A majority of model organism research (especially in mice
and rats) has focused on minimizing both genetic and environmental variability—a
principle that the use of inbred lines takes to an extreme. However, this means that
while we can learn about biological mechanism from genetic studies using such mod-
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els, the generalization of results from these models to identify pathogenic variants
may be limited. This field may have to re-invent itself to become a better model for
complex phenotypes in complex human populations.
When the human genome was first mapped in 2001, Bill Clinton described it as
“the most wondrous map ever produced by humankind. . . today we are learning the
language in which God created life”. While we are well on our way to having read
the script (and are beginning to find ways to edit it [25]), we are still understanding
its grammar. In the next decade, we are likely to have multiple layers of information
on the genome and the phenome. Integrating these judiciously will be a key tool in
deciphering the algorithms of the genome.
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